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ABSTRACT
Computational Modeling to Study Disease Development: Applications to Breast Cancer
and an In Vitro Model of Macular Degeneration
by
Qanita Bani Baker, Doctor of Philosophy
Utah State University, 2015

Major Professor: Dr. Nicholas S. Flann
Department: Computer Science
The progression of many diseases, such as breast cancer and age-related macular degeneration, is not fully understood. These diseases are mechanistically complex, nonlinear,
and are driven by complex interacting processes that occur at different scales of time and
space. When paired with traditional biological investigations, computational models can
play a significant role in understanding disease progression, because computational models
formalize and quantify mechanisms between interacting components and can test hypotheses about pathogenesis orders of magnitude faster than biological investigations. The results
of these computational studies can then be used by biologists to inform their in vivo studies,
and meaningful insights can be gained into disease, i.e., how to control its progression and
how to treat it.
The ability of agent-based models to encompass multiple spatiotemporal scales of biological process makes this modeling framework well suited to explore biological systems
and disease development. In this dissertation, we extend a multicellular hybrid agent-based
modeling approach and use it to study the development of breast cancer and to better understand an in vitro model for age-related macular degeneration (AMD). To achieve this,
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we needed to identify methods, algorithms and techniques that increase the effectiveness of
agent-based models applied to disease development.
The transition in breast cancer from ductal carcinoma in situ to invasive ductal carcinoma was studied in the framework of two-dimensional breast duct structures. This model
includes ductal, stromal and tumor cell types acting along with multiple biochemical and
biomechanical interactions. The results of the model were qualitatively validated using
micrographs of progressing ductal carinoma and biochemical and biophysical properties reported in the literature. We also developed and applied an in silico model to an in vitro
model of age-related macular degeneration. This in vitro model uses retinal cells grown
in culture in territories of different controlled size to explore how the distribution of cells
effects the production of vascular-endothelial growth factor (VEGF). VEGF overproduction plays a central role in AMD. The agent-based model was used to study the underlying
mechanism of VEGF production, and predict the VEGF with varying configurations of
cells. The model was quantitatively validated from experimental in vitro data. We developed an error-minimizing searching approach that uses available information about VEGF
metabolism at the cell population level to predict currently unknown parameters of VEGF
metabolisms at the cell level, essentially bridging the gap in scales between the multicellular
and cellular levels of organization.
(121 pages)
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PUBLIC ABSTRACT
Computational Modeling to Study Disease Development: Applications to Breast Cancer
and an In Vitro Model of Macular Degeneration

Qanita Bani Baker

There have been several techniques developed in recent years to develop computer
models of a variety of disease behaviors. Agent-based modeling is a discrete-based modeling
approach used agents to represent individual cells that mechanically interact and secrete,
consume or react to soluble products. It has become a powerful modeling approach, widely
used by computational researchers. In this research, we utilized agent-based modeling to
study and explore disease development, particularly in two applications, breast cancer and
bioengineering experiments. We further proposed an error-minimization search approach
and used it to estimate cellular parameters from multicellular in vitro data.
In this dissertation, in the first study, we developed a 2D agent-based model that attempted to emulate the in vivo structure of breast cancer. The model was applied to describe
the progression from DCIS into DCI. This model confirms that the interaction between tumor cells and the surrounding stroma in the duct plays a critical role in tumor growth and
metastasis. This interaction depends on many mechanical and chemical factors that work
with each other to produce tumor invasion of the surrounding tissue. In the second study,
an in silico model was developed and applied to understanding the underlying mechanism
of vascular-endothelial growth factor (VEGF) auto-regulation in REP and emulate the in
vitro experiments as part of bioengineering research. This model may provide a system with
robust predictive modeling and visualization that could enable discovery of the molecular
mechanisms involved in age-related macular degeneration (AMD) progression and provide
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routers to the development of effective treatments. In the third and final study, a searching
approach was applied to estimate cellular parameters from spatiotemporal data produced
from bioengineered multicellular in vitro experiments. We applied a search method to an
integrated cellular and multicellular model of retinal pigment epithelial cells to estimate the
auto-regulation parameters of VEGF.
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ACRONYMS
ABM Agent-Based Model. One of a class of computational models for simulating the
actions and interactions of autonomous agents (both individual or collective entities
such as organizations or groups) with a view to assessing their effects on the system
as a whole..
AMD Age-related Macular Degeneration. A deterioration or breakdown of the eye’s macula. The macula is a small area in the retina that is the light-sensitive tissue lining
the back of the eye. The macula is the part of the retina that is responsible for central
vision, allowing one to see fine details clearly.
CA Cellular Automata. A class of spatially and temporally discrete mathematical systems
that are characterised by local interaction and synchronous dynamical evolution.
DCIS Ductal Carcinoma in Situ. The presence of tumor cells inside a milk duct in the
breast. DCIS is a noninvasive condition. DCIS can progress to become invasive cancer,
but estimates of the likelihood of this vary widely.
ECM Extracellular Matrix. A collection of extracellular molecules secreted by cells that
provide structural and biochemical support to the surrounding cells. It forms a meshwork of proteins and carbohydrates that binds cells together or divides one tissue from
another.
ECs Epithelial Cells. Cells that line the inner and outer surfaces of the body by forming
cellular layers (EPITHELIUM) or masses.
IDC Invasive Ductal Carcinoma. The cancer cells that began forming in the milk ducts
and have spread beyond the ducts into other parts of the breast tissue. Invasive cancer
cells can also spread to other parts of the body. It is also sometimes called infiltrative
ductal carcinoma.
LOX Lysyl Oxidase. A copper-dependent amine oxidase enzyme that initiates the crosslinking of collagens and elastin. It plays a critical role in the biogenesis of connective tissue
matrices by crosslinking the extracellular matrix proteins, collagen and elastin.
MEs Myoepithelial Cells. Smooth, musclelike cells of ectodermal origin, found between
the epithelium and basement membrane in the surface of some acini of the salivary
glands, which is believed to be responsible for facilitating the secretion of fluids from
the gland.
MMPs Matrix Metalloproteinase. Also called matrixins. A large family of calciumdependent zinc-containing endopeptidases, that are responsible for the tissue remodeling and degradation of the extracellular matrix. They play major roles in morphogenesis, wound healing, tissue repair and remodelling in response to injury.

xvii
RPE Retinal Pigmented Epithelium or Retinal Pigmented Epithelial (when used in the
context of ”cell”). The pigment cell layer that nourishes the retinal cells. It is located
just outside the retina and is attached to the choroid, a layer filled with blood vessels
that nourish the retina.
TCs Tumor Cells. An abnormal growth of tissue resulting from uncontrolled, progressive
multiplication of cells and serving no physiological function.
TGF-β Transforming Growth Factor Beta. A secreted protein that controls many cellular
functions, including cell growth, cell proliferation, cell differentiation and apoptosis.
VEGF Vascular Endothelial Growth Factor. A signal protein produced by cells that stimulates vasculogenesis and angiogenesis
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CHAPTER 1
INTRODUCTION
Biological systems are intrinsically complex. They are operate on multiple functional
scales that span across multiple temporal and spatial domains at scales from the atomic
level (10−10 m) to the whole living organism (1 m), and from nanoseconds (10−9 s) to years
(108 s) (Figure 1.1). A successful understanding of biological function emerges if all relevant
information at several levels of organization is integrated, as discussed in [6–8]. For example,
in the context of heart function and pathology, Noble [9] illustrated how the success of drug
therapy depends not only on understanding the functions at the protein level, but also
on knowing how a protein interacts with its surrounding cellular machinery to generate
functions at a higher level. There is no doubt that an understanding of the inter-scale and
intra-scale interactions is critical to the study of human diseases and potential treatments.
The need to model complex temporal and spatiotemporal processes at many scales has
led to the emergence of numerous computational modeling techniques including systems of
differential equations, cellular automata simulators, and agent-based models [10]. Multiscale computational models provide unique capabilities to capture the connectivity between
diverse scales of biological function [11,12] and they can also bridge the gap in understanding
between in vitro experiments and in vivo models [13–15]. The advent of powerful computing
systems, combined with quantitative data from high-throughput experimental platforms,
has expanded multi-scale modeling more comprehensively investigate biological phenomena
[16].
The main challenge in multi-scale modeling is maintaining the balance between the
computational complexity of the model and its fidelity [17]. The level of model resolution
is tightly coupled to computational complexity, where the computational load increases as
a function of the model details [18]. Computational modeling that aims to explore such
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Figure 1.1. Multiscale models of the human body targeting complex processes that span
diverse time and length scales of biological organization [2].

multi-scale systems has to incorporate several techniques because of the diverse time and
space scales involved. In section 1.1 we provide an overview of different approaches and
techniques used to handle these tasks. Then, in Section 1.2, we summarized the main
objectives for the research performed in this dissertation. In Section 1.3, we present the
projects that were included in this research. In Section 1.4, the research methodology and
strategies are explained. Finally, we demonstrate the impacts of the research in Section 1.5.

1.1

Modeling Approaches and Techniques in Computational Systems Biology

1.1.1

Top-down, Middle-Out, or Bottom-up Approaches

There are three approaches to multiscale modeling: top-down, middle-out or bottomup [19]. The bottom-up approach begins with modeling the system components in isolation
and then integrating them to study the emergent properties and predict the behavior of
the entire system. The basic principle of the bottom-up approach is to mathematically or
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graphically model relationships between the system's components, starting from the lowest
level of the multi-scale structure, such as genes and proteins, setting model parameters based
on available experimental values, then verifying the model by comparing its behaviors with
real system behaviors [20, 21]. The bottom-up approach has a computational problem,
which comes from the difficulty and complexity of the integration process across multiple
scales. Also, the limitations of bottom-up understanding, as well as a lack of knowledge of
many cellular- and tissue-level responses to stimuli that could be used to validate models,
present additional long-term, fundamental challenges [22].
Top-down approaches start by considering biological properties and behaviors in the
whole system. These behaviors are then used to develop a model that can describe the
high-level properties used discover and characterize biological mechanisms at lower levels.
Basically, the top-down approach involves defining ways in which the systemic function of
interest varies with time or/and conditions, then inferring hypothetical lower-level structures
responsible for this function. For instance, in [23], the researchers presented a top-down
approach to modeling the single-chain antibody folding pathway [24, 25]. After the scope
of the model was established, model development started with the construction of the most
basic mathematical model. Incrementally, they appended desired biological details to the
developing model and evaluated their effects on model performance until the desired level
of detail had been achieved. The top-down approach is applicable to systems of all sizes
and with all amounts of available biological information [26].
The third modeling strategy is the middle-out approach, which begins with an intermediate scale such as a cell, then is gradually expanded to include both smaller and larger
scales. The middle-out approach is designed to overcome the intrinsic limitations of the
above approaches, and it is typically constructed and tested at the levels where we have
the most detailed information [27, 28]. For example Noble [9] used a middle-out approach
in modeling the heart that it benefited from the wealth of accessible experimental data
available at the cellular level and the data-rich modeling of the 3D geometry of the whole
heart. In this dissertation, developed for ductal carcinoma in situ is a bottom-up approach
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and the model developed for studying VEGF metabolism is a middle-out model.

1.1.2

Continuum, Discrete, or Hybrid Techniques

Modeling can take: discrete, continuum, or hybrid approaches. Continuum models use
partial differential equations that are capable of capturing larger-scale systems and provide
insight into the relationship among the components of the system. They can be used for
modeling several levels of biological systems. Although a continuum model is relatively
quicker and easy to implement, it does not capture the discrete nature of systems consisting
of individual cells and becomes limited when it is used to model a complex process involving
multiple variables [29, 30].
On the other hand, in discrete models, individual cells are explicitly represented in
space and time. In these models, individual cell behaviors and interactions with other
cells and with the environment can be simulated, enabling emergent system behaviors and
properties. Discrete models are usually limited to relatively small numbers of cells due to a
large computational demand, and as a result a typical discrete model is usually designed with
low domain size [31, 32]. Two major, related discrete modeling strategies currently exist:
Cellular Automata (CA) and Agent-Based Model (ABM). A typical CA is a collection of
cells on a grid of specified shape. CA has a finite set of cell states, a regular discrete lattice,
a finite set of neighboring cells, and rules for the transition of cell states, such as division,
migration, apoptosis, and differentiation [29, 29, 33]. In contrast, an ABM asynchronously
represents phenomena as dynamic systems of rule-based interactions among agents and their
environment, following a set of rules. It is a rule-based, discrete-time, and discrete-event
computational modeling methodology that employs computational objects called agents, as
in [34–37]. ABM and CA are similar in that the behaviors of agents or cells are controlled by
the rules in their environment or neighborhood, both belong to the bottom-up approach, and
global emergent proprieties and behaviors are generated from local interactions. However,
CA models impose a simpler quantization space which is unrealistic and limits fidelity, thus
CA is weaker in its spatial representation [10]. Recently, agent-based models have become a
powerful framework, widely used by computational biological and cancer researchers, since
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Figure 1.2. A diagrammatic representation of several biological scales and their associated
modeling techniques and experimental approaches as in [3].

they have potential to encompass several scales of biological organization and the locations
of the agents.
A promising alternative modeling technique is the hybrid models which combine discrete and continuum approaches, and take the strengths of each approach. Recently, hybrid
models have attracted considerable attention due to their success in many biological application [38–41]. The models developed in this dissertation are hybrid models that consider
particles - the discrete component - and soluble products, such as diffusion proteins, and
nutrient - the continuous part of the model.
A choice among modeling approaches should depend on the biological questions that
are being addressed. Establishing which model framework to use and what level of detail to include still remain open questions. Many researchers provide strategies and tactics that can help in choosing a suitable approach based on the problem characteristics.
Meier-Schellersheim et al. [3] provided an overview of how different scales of experimental research can be combined with the appropriate computational modeling techniques to
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carry out multi-scale modeling of cell-to-organ systems as summarized in Figure 1.2. In
this dissertation, we develop a hybrid, agent-based framework to model the transition in
breast cancer from ductal carcinoma in situ to invasive ductal carcinoma (Project 1), and
study the effect of retinal pigment epithelial cell patch size on VEGF expression (Project
2). Finally, we fit the developed model in Project 2 to available in vitro experimental data,
so as to estimate the model's parameters (Project 3).

1.2

Objectives
The core goal of this research is to utilize a multicellular hybrid agent-based modeling

approach in studying disease development and progression. The major question on which
this research focuses is: how can a hybrid agent-based modeling approach be utilized to
study and explore disease development, particularly in two applications, breast cancer and
bioengineering experiments related to AMD? To achieve this, we need to identify methods,
algorithms and techniques that increase the effectiveness of these models. We have realized
this overall goal by completing three specific aims:
The first aim of the dissertation is to introduce a multicellular agent-based model of
ductal carcinoma in situ growth and invasion that includes ductal, stromal and tumor cell
types acting along with multiple biochemical and biomechanical interactions. This model
replicates the disease state associated with breast cancer from initiation to invasion. This
work provides a robust predictive modeling and visualization system to enable discovery
of molecular mechanisms involved in tumorigenensis and metastasis, testing of candidate
therapeutics, and more rapid identification of therapeutics against malignancy.
The second aim of this dissertation is to apply an agent-based framework to provide
an in silico model that can be used to understand a central aspect of an in vitro model for
age-related macular degeneration (AMD): the effect of retinal pigment epithelial cell patch
sizes on growth factor expression. This framework provides a model for emulating disease
states associated with the deterioration of retinal tissue during AMD.
The third and final aim of this dissertation is to develop an alternative approach to
bridge the multi-scale gap by identifying cellular biochemical and biophysical parameters
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from multicellular data. A search method is developed and applied to estimate cellular
parameters related to VEGF metabolism from spatiotemporal data available from a bioengineered multicellular in vitro model of AMD development. The method successfully
identifies values for VEGF properties that can be used in the model produced in Project 2
to reproduce the spatiotemporal derived from in vitro experimental data.

1.3

Projects Outlines

1.3.1

Project 1: Interactions of Stroma and Tumor Cells in Carcinoma in Situ
to Invasion: An Agent-Based Modeling Approach

Breast cancer is one of the main causes of cancer-related deaths in women. In situ
ductal carcinoma of the breast is the most common precursor to invasive ductal carcinoma
(IDC). Ductal carcinoma in situ (DCIS) develops over two to twelve years [42] and is not
a life-threatening cancer, but is clinically important because it can be detected and treated
before the duct is breached allowing the tumor to invade neighboring tissues. Left untreated,
14%-15% of DCIS progress to invasive cancer [43].
In this project, we developed a multicellular agent-based model of ductal carcinoma
growth and invasion that includes ductal, stromal and tumor cell types, transforming growth
factor beta (TGF-β), matrix metalloproteinase (MMP), lysyl oxidase (LOX), and extracellular matrix (ECM) protein assemblies, including the basement membrane. Unlike models
that consider only biochemical inputs, the model developed in this work explicitly determined tensional and compressive forces within the developing tissue along with the distributions of and cellular responses to biochemical agents. The model demonstrated that MMP
secretion sufficiently weakens the ductal basement membrane and epithelial tight junctions
to undermine ductal integrity and that compressive and tensile stress within the growing
tissue contributes to metastasis.
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1.3.2

Project 2: Developing An in Silico Model to Study The Effect of Retinal
Pigment Epithelial Cell Patch Sizes on VEGF Production

Age-related macular degeneration (AMD) is a leading cause of irreversible blindness
world -wide [44,45]. Degeneration of retinal pigment epithelial (RPE) cells severely damages
the visual function of retina photoreceptors. Age-related alterations of the RPE include
changes in pigmentation and the reduction of cell density of RPE [46]. There are two
forms of AMD: dry (atrophic) and wet (exudative). In exudative AMD, new blood vessels
from the underlying choriocapillaris grow toward the RPE. These processes often lead to
irreversible loss of the central visual field [47]. Anti-VEGF therapy is used to treat exudative
AMD because of the central role that VEGF plays in neovascularization. In vitro studies
provide powerful tools for examining the links between growth factor expression, tissue
reorganization and the progression of the disease, and replicate the effect of atrophic and
leaky RPE cells on VEGF expression. However, the stimuli leading to enhanced VEGF
secreted from RPE cells and the subsequent neovascularization processes in the choroid are
still not fully understood [48, 49].
Vargis et al. [1] used the bioengineered micropatterning techniques to create a regular
arrangement of circular colonies, called patches, populated with RPE cells surrounded by a
empty substrate. Creation of this micropatterns involves many sequential steps. The nonpopulated regions imitate necrotic regions in the retina that result from repeated exposure
to reactive oxidative species, triggering death of the retinal pigment epithelium followed by
death of the overlying photoreceptors and neovascularization, which is leading exudative
AMD [50, 51].
The goal of this study was to develop a computational model to replicate the in vitro
cellular model [1], and then to use the computational model to study how different configurations of cells influenced on VEGF expression. Quantitative analysis of RPE patch
morphology and VEGF expression was performed. VEGF levels in each patch were studied
as a function of cell number and patch area through time. VEGF expression from various sized patches was quantified following VEGF agonist administration in order to study
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the hypothesis that VEGF expression is linked to VEGF auto-regulation in the microenvironment [52, 53] through targeting VEGF [54]. This work complements the experimental
studies performed in vitro and provides a framework that can be used to study the influence
of cell patterning on the secretion of VEGF by RPE tissue. The model has potential to
point toward a path to mimicking the effects of tissue damage or atrophy that occurs in the
retina during AMD. This model was applied to study additional mechanism and predict.

1.3.3

Project 3: Bridging the Multiscale Gap: Identifying Cellular Parameters
from Multicellular Data

One of the main challenges in the computational modeling of biological systems is
identifying values of model parameters. This problem is particularly acute with multiscale
models. In this project, we developed an approach that estimates cellular parameters from
spatiotemporal data produced from in vitro studies.
We developed a search technique to discover the values of biochemical parameters related to VEGF metabolism. The method began with data available from a multicellular
model of retinal pigment epithelial cells. Understanding VEGF regulation is critical in treating AMD and many other diseases. Thousands of simulations were performed as the search
method explored the parameter space. For each potential solution, multiple simulations
were needed over each experimental case (different patch sizes) and because of the need for
repeats due to model stochasticity. The method successfully identifies realistic values for
VEGF autoregulatory parameters that reproduce the spatiotemporal in vitro experimental
data.

1.4

Research Methodology and Strategies
The using modeling framework is an extension of iDynoMiCS [55], which is a hybrid

agent-based modeling framework and originally developed to simulate biofilm development.
Two major components of the framework are particles and soluble products, integrated
within a reaction diffusion system. Particles, the discrete part of the model, represent
individual cells that mechanically interact, secrete, consume or react to soluble products.
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Soluble products represent extracellular diffusible biomolecules that make up the continuous
component of the system whose distributions are determined by a diffusion solver that
resolves all the local changes in concentration induced by the particle secretion and uptake
and long-range diffusion.
In Project 1, the DCIS model was executed from an normal duct configuration at model
initialization and run to simulate the development of the ductal tumor from initiation
to ductal breach and invasion. This model is complex and includes a large number of
parameters, including some parameters that cannot yet be measured. First, the known
parameters were set from the literature, then the other parameters were estimated and
refined by evaluating the ability of the model to recapitulate observed tumor progression.
The model was limited to a relatively small numbers of cells due to the large computational
demand, and as a result the model was defined over a small domain size as shown in Figure
2.5. Several assumptions were taken into consideration in the design of the model. For
example, it was assumed that the ductal tissue has a limited number of fibroblasts that do
not grow.
In Project 2, the RPE model was executed from the initial experimental conditions and
simulated the in vitro model of VEGF metabolism from 1-72 hours. The known parameters
were set from the experimental data in [1]. Unknown parameters (VEGF secretion rate
of each RPE cell, VEGF binding affinity, and autoregulation strength were randomly initialized; then they were refined based on the results of the optimization process in Project
3. The ultimate goal of any modeling effort is to provide actionable predictions. Ideally,
important experiments that could not be performed in vitro could instead be done using
the in silico approach. For instance, a more realistic model of retinal degeneration is a
configuration is which there are cell-free areas in the midst of a largely cell-covered surface
of the culture dish. This was modeled using circular patches were the cells are applied to
the outside areas and the patches were left empty. This arrangment is the inverse used in
the engineered in vitro cellular model and it provides a more realistic configuration.

11
In Project 3, the main objective is to develop a general-purpose techniques for determining the free parameters, error functions, realistic ranges, experimental measurements,
search space constraints, and refinement operators. In order to minimize the error and identify likely values for the free-parameters in the model developed in Project 2, thousands of
simulations are required. A single execution of the model can take hours, and hundreds of
simulations must be run to identify the sensitive parameters, to adjust their ranges and to
study model behavior. These computational challenges were taken in consideration, and we
used several fast machines(The memory for each machine is 16GB RAM, and the processor
is Intel(R) Core(TM) i7-3770K CPU, 3.50GHz (eight CPUs))to run the experiments 24
hours a day.

1.5

Research Impacts
The work in Project 1 could provide a system with robust predictive modeling and

visualization to enable discovery of molecular mechanisms involved in tumorigenesis and
metastasis, testing of candidate therapeutics, and more rapid identification of therapeutics
against malignancy. In addition, the emphasis on the interaction between biochemical and
biomechanical properties in cancer progression may open the door to new treatments that
exploit these mechanisms. We believe this model will have higher impacts in the future
when this model is integrated with histological clinical and experimental data, such as that
being collected in the TCGA project [56, 57].
The work in Project 2 complements experimental studies performed in vitro and provides an in silico framework with reliable predictive modeling and visualization to examine
the effects of the spatial organization of retinal pigment epithelial (RPE) cells grown in
patches of several sizes on VEGF production. It could aid in the development of agents
that target VEGF and inhibit angiogenesis, and may be useful in evaluating biomarkers
of anti-angiogenic therapies in age-related macular degeneration. This work models the
bioengineered multicellular configurations that provide strong experimental controls and
customizations to target specific cellular mechanisms.
The multicellular search-based approach introduced in Project 3 is applied to identify
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the parameter values of a cellular regulatory mechanism using spatiotemporal multicellular
data. This approach was applied to predict the dynamic concentrations of VEGF and other
VEGF parameters that are difficult to quantify experimentally. In addition, the results
may aid understanding of how uncertainty in the values of particular parameters influence
model outputs.
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CHAPTER 2
AN AGENT-BASED MODELING APPROACH TO
EXPLORE INTERACTIONS OF STROMA AND TUMOR
CELLS: THE PROGRESSION OF IN DUCTAL
CARCINOMA IN SITU TO INVASIVE DUCTAL
CARCINOMA

2.1

Abstract
Invasive ductal carcinoma marks a significant drop in patient survival and is one of the

leading causes of death in women. The timing and severity of ductal breach is primarily
driven by biochemical and biomechanical mechanisms that interact to weaken duct integrity
and induce stress in the duct wall. Understanding the cellular responses to these biomechanical and biochemical stimuli may lead to new therapeutic approaches to breast cancer. We
introduce a multicellular agent-based model of ductal carcinoma growth and invasion that
considers ductal, stromal and tumor cell types, transforming growth factor beta (TGF-β),
matrix metalloproteinases (MMPs), lysyl oxidase (LOX), extracellular matrix (ECM) protein assemblies, including the basement membrane, and that explicitly determines tensional
and compressive forces within the developing tissue along with the distributions of and cellular responses to biochemical agents. The model predicts that MMP secretion sufficiently
weakens the ductal basement membrane and epithelial tight junctions to undermine ductal
integrity and that compressive and tensile stress within the growing tissue contributes to
metastasis.
0
The coauthors for this chapter are: Qanita Bani Baker, Ahmadreza Ghaffarizadeh, Soonjo Kwon,
Gregory J. Podgorski and Nicholas S. Flann
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2.2

Introduction
Breast cancer is one of the main causes of cancer-related deaths in women. Ductal

carcinoma in situ (DCIS) of the breast is the most common precursor to invasive ductal
carcinoma (IDC). Ductal carcinoma in situ develops over two to twelve years [42] and is not
a life-threatening cancer, but is clinically important because it can be detected and treated
before the duct is breached. Clinical studies show that 14%-53% of misdiagnosed DCIS, if
left untreated, will progress to invasive cancer [43].
Breast ducts are composed of radial layers of cells and extracellular matrix. Moving
from the lumen outwards, these layers are epithelial cells (ECs), basement membrane, and
myoepithelial cells (MEs) surrounded by stroma consisting of ECM, fibroblasts, myofibroblasts, and blood vessels (see Figure 2.1a). Figure 2.1 shows the steps in the transition
from normal ducts to an invasive carcinoma [4]. DCIS occurs when abnormal epithelial
cells begin growing within the duct. These are tumor cells (TCs) and they exert outward
biomechanical stress on the ductal system of epithelial cells, myoepithelial cells and the
supporting basement membrane and also secrete proteinases which weaken the ductal wall
and trigger biomechanical changes in the surrounding stroma.
While the progression from DCIS to IDC is understood in outline, many open questions
on DCIS biology remain. How do the mechanical properties of breast tissue contribute to
disease progression, compromise treatment or alter metastasis risk? How does inter ductal
pressure influence tumor progression, metastasis, and responses to cancer therapy? How are
the material properties of breast tissues established and maintained? How do cells adapt
to biochemical and biophysical changes that occur during in situ tumor growth? Answers
to these questions have important implications for clinical practice.
The simulation system developed here may aid in answering these questions. The
objective of this paper is to explore the interplay between the buildup and relief of forces
within the duct as a tumor grows and as both the cells and ECM change their biophyscial
properties in response to these forces. The model also considers how biochemical events,
such as activation of growth factors and production of enzymes that change the mechanical
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Figure 2.1. a- The developing of normal breast. b- The transition from normal mammary
ducts to an invasive tumor in breast cancer. From Butcher et al. 2009 [4]

properties of the ECM, shape the unfolding biomechanical dynamics of the duct during
tumor growth. The emphasis on the interaction between biochemical and biomechanical
properties in cancer progression may open the door to new treatments that exploit these
mechanisms.

2.3

Background

2.3.1

Previous Models of Ductal Carcinoma in situ

Many of computational approaches and modeling paradigms have been developed to
understand and predict the dynamics of DCIS and its transition to IDS. Current computational cancer modeling approaches fall into three main categories: discrete, continuum, or
hybrid approaches [37]. Continuum models usually use partial differential equations that are
capable of capturing larger-scale systems and provide insight into the relationship among
the components of the system. Continuum models can be used for modeling several levels
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of biological systems. While a continuum model is relatively quick and easy to implement,
it does not capture the discrete nature of systems consisting of individual cells and becomes
limited when it is used to model a complex process involving multiple variables [29, 30].
On the other hand, in discrete models, individual cells are explicitly represented in
space and time. In these models, individual cell behaviors and interactions with other
cells and with the environment can be simulated enabling emergent system behaviors and
properties. Discrete models are usually limited to relatively small numbers of cells due to a
large computational demand, and as a result a typical discrete model is usually designed with
low domain size [31, 32]. Two major, related discrete modeling strategies currently exist:
Cellular Automata (CA) and Agent-Based Models (ABMs). A typical CA model considers
a collection of cells on a grid of specified shape. CA models usually include a finite set of cell
states, a regular discrete lattice, a finite set of neighboring cells, and rules for the transition
of cell states, such as division, migration, apoptosis, and differentiation as explained [29,
33]. In contrast, ABM models represent phenomena as dynamic systems of rule-based
interactions among agents and their environment, using discrete-time, and discrete-event
modeling methodology [34–37]. ABM and CA modeling approaches are similar in that the
behaviors of agents or cells are controlled by their environment or neighborhood, and both
are bottom-up modeling approachs, and global system emergent proprieties and behaviors
are generated from local interactions. However, CA models impose a simple quantization
space that is unrealistic and limits fidelity, thus the CA modeling approach is weaker in its
representation of space [10]. ABMs have recently been more widely used by computational
biological and cancer researchers, because of their potential to encompass several scales
of biological organization and their robust ability to consider the spatial arrangement of
agents.
Even more promising alternative modeling techniques are hybrid models which combine discrete and continuum approaches and take advantage of each approach. Recently,
hybrid models have attracted considerable attention due to their success in many biological
applications [38–41]. The work reported here applies an agent-based modeling framework
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to perform a study into how biomechanical and biochemical processes interact within ductal
and stromal cells to trigger DCIS to IDS transition.
Franks et al. [58] described the initial stages of DCIS, where a nutrient-limited growth
model was introduced that used Stokes flow to describe the behavior of the tumor cells. They
applied numerical and asymptotic methods to examine the shape of the tumor boundary and
the extent of tumor cell adhesion to the duct wall in early DCIS. They extended this work
in [59] to develop a continuum mathematical model that was used to examine the effects
of proteolytic enzyme production on tumor growth and invasion. This model predicts that
mechanical stress on the duct wall is the dominant mechanism in the transition of invasive
carcinoma.
Sontag and Axelrod [60] combined a population-scale model with machine learning
techniques and statistical analyses to describe the progression from DCIS to IDC. Here four
signalling pathways were investigated that describe relationships between different grades
of DCIS and IDC found in the same patient.
Rejniak and Dillon [61] employed a cell-based technique to make predictions for DCIS
morphologies based on differential growth and cell polarity. Their model utilized the immersed boundary method that treats cells as elastic bodies and models the cytoplasm and
extracellular matrix as viscous incompressible fluids. They found that the formation of the
four specific DCIS morphologies (micropapillary, cribriform, tufting, and solid) result from
changes in cell orientation and growth rates.
Figueredo et al. [62] compared agent-based modeling approaches to approaches that use
ordinary differential equations. They considered three case studies using models of immune
interactions within early-stage DCIS. They demonstrated that the stochastic elements that
are essential components of agent-based models increase fidelity and provide unique insights
beyond those of models based on differential equations. Norton et al. [63] developed a 2D
model using a lattice-free agent model and conducted an investigation of the relationship
among polarised cell adhesion, intraductal pressure, and subsequent DCIS morphology.
Kim et al. [64] applied an agent-based model to study interactions among DCIS cells and
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stromal cells via TGF-β and EGF soluble factors; their work included the effects of basement
membrane expansion. Macklin et al. [65] developed an agent-based cell model and applied
it to the process of necrosis in tumor morphology. In this work the first patient-specific
calibration method was introduced to help constrain the model based on clinically-accessible
histopathology data. Their work illustrated how computational modeling can provide new
insights into the biophysical underpinnings of cancer. D’Antonio et al. [66] introduced an
agent-based model to simulate the interactions between cells and the basement membrane.
They modeled the basement membrane as a linked series of Hookean springs, each with
time-varying length, thickness, and spring constant. In this model, each BM spring node
exchanges adhesive and repulsive forces with the cell agents. Also, they modeled elastic
BM-ECM interactions with analogous ECM springs. They found that varying the balance
of BM and ECM elasticity can trigger heterogenous distribution of BM thickness that can
lead to ductal breaching.

2.3.2

Key Biological Components involved in Ductal Carcinoma in situ progress

The accumulation of genetic and epigenetic alterations in the ductal epithelium cellsa
ccompanied by alterations in the matrix leads to unchecked proliferation and enhanced
proliferation of luminal epithelial cells within the ductal tree [67]. With prolonged growth,
luminal mammary epithelial cells eventually expand to fill the breast ducts.
Importantly, the abnormal luminal mammary epithelial cells secrete soluble factors
including MMPs that diffuse into the stromal matrix. MMPs are a family of zinc- and
calcium-dependent proteinases that degrade the collagen of the ECM and stimulate the
expression of fibronectin through the activation of transforming growth factor-beta (TGFβ). The TGF-β is released as an inactive latent complex. Latent TGF-β can be activated
by metalloproteases MMP-9 and MMP-2, which are often expressed by malignant cells [68],
[69].
TGF-β activate resident fibroblasts to differentiate into myofibroblasts which are responsible for the changes in the composition, post-translational modifications and topology
of ECM proteins, causing the ECM to stiffern over time. The number of myoepithelial
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cells surrounding the abnormal luminal mammary epithelial cells mass decreases and the
basement membrane thins, probably owing to increased (MMP) activity, decreased protein
deposition, and compromised epithelial tight junctions [70], [71].
In the non-malignant state structural and metabolic proteins are present in the ECM.
A subset of ECM proteins are overexpressed in the surrounding stromal matrix during
tumorigenesis. ECM remodeling is driven by:
1. The increased levels of (LOX)-dependent ECM cross-linking [72], [73]. LOX is an
amine oxidase which catalyzes the conversion of lysine and hydroxylysine residues in
collagen molecules to their semi-aldehydes. This is the first step in forming of covalent
intra- and intermolecular collagen crosslinks, and the creation of collagen fibrils and
fibers to stabilize the mechanical integrity of collagen. Thus, LOX plays an important
role in vivo in the stabilization of newly synthesized collagen and the stiffening of
ECM [74], [75], [76].
2. Abnormal MMPs expression and function [77], including overexpression of MMP2 in
the transformed ECs [78] and MMP3, MMP11, MMP12, and MMP13 in the tumor
stroma. The synthesis and degradation of the ECM of the stromal matrix also depends
on a balance between another class of MMPs and their tissue inhibitors (TIMPs).
3. Post-translational modifications of ECM proteins including altered deposition of proteoglycans [79], [80].
In this study, to model DCIS progression to IDC, we introduced a multicellular agentbased model of ductal carcinoma growth and invasion in a way that incorporates ductal,
stromal and tumor cell types, transforming growth factor beta(TGF-β), matrix metalloproteinase (MMP), lysyl oxidase (LOX), and extracellular matrix (ECM) protein assemblies,
including the basement membrane. This model can visualize and predict how perturbation
of the local biochemical and biomechanical state influence DCIS evolution.
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2.4

Methods

2.4.1

Domain-Independent Agent Based Model

Our modeling framework is an extension of iDynoMiCS [55], a modeling framework
that was originally developed to simulate biofilm development. Two major components
of our model are particles and soluble products integrated within a reaction diffusion system. Particles, the discrete part of the model, represent individual cells that mechanically
interact and secrete, consume or react to soluble products. Soluble products represent extracellular diffusible biomolecules that make up the continuous component of the system.
The distribution of the biomolecules is determined by a diffusion solver that resolves all the
local changes in concentration induced by cell physiology and diffusion.

Particles
A particle is an incompressible sphere with a mass and set of regulatory components
that depends on its type. The particle is positioned in space and occupies the volume of
a single cell. Particles grow and mechanically interact with each other through packing
constraints, pressure relief, adhesion, chemotaxis and other mechanisms. Signalling among
particles is implemented through diffusion. Particles can be specified to represent distinct
cell types through assignment of unique reaction-diffusion equations and biomechanical
properties such as adhesion. Switching between cell states is possible and is triggered by
the properties of the particle’s internal state and external environment.

Particle Dynamics
A configuration of particles represents the spatiotemporal state of the biological system.
To update the configuration, the net force acting on each particle is first determined, then
the particles are moved based on a force vector that is determined dynamically as the model
runs. The mechanical forces acting on a particle (σi ) are computed by vector addition of
force contributions of each mechanism in play during the simulation, Fm (σi , σj ) where i, j
are indexes to each near-by particle and m is the specific mechanism. Since the particles
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are over damped, inertial effects are ignored and particle velocity is proportional to force.
A weak stochastic force η is added to each particle to model underlying fluctuations in cell
movement using a Gaussian distribution with a variance of 0.1; this stochastic movement
is essential for reaching cellular configurations of near-minimum energy.
The change in position of an arbitrary particle σi , denoted as ∆p(σi ) is defined as:

∆p(σi ) = (Σm∈M Σj Fm (σi , σj ) + Σl∈M Fl (σi ) + η)∆t

(2.1)

Once forces are generated, a relaxation algorithm is executed to determine the quasisteady state that minimizes the forces acting on the system. The process continues until
the magnitude of particle movement drops below some threshold. The complete particle
configuration is asynchronously updated by randomly selecting each particle then applying
a small displacement based on equation 2.1 to avoid artifacts.

Growth and Mass Decay
Growth reactions lead to changes in the biomass of a particle. As the biomass increases
so does the spherical particle volume and radiuse. When the radius equals or exceeds a
maximum type-specific particle size parameter called the split radius Rsp , the particle is
divided in two along a random cleavage plane. Any overlap with neighboring cells is ignored
during placement and resolved during force relaxation.
Particle size can reduce through biochemical reactions that consume biomass or lead
to decay, particle apoptosis,or necrosis. When the radius equals or falls below the minimum
particle size parameter called the death radius (Rd ), the particle is removed from the domain.

Pairwise Particle Interaction
Packing constraints cause particles to exert opposing forces (positive) on each other to
minimize spatial overlapping caused by growth or cell movement. The process is illustrated
in Figure 2.2. In this work, the opposing force magnitude is directly proportional to the
overlap distance between each particle. So
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(a) particle shoving

(b) particle/boundary shoving

Figure 2.2. Particle Shoving: Rt (σi ) is the radius of a particle of state t(σi ), αt is the
shoving factor for this state t and d is the distance between the objects. When two particles
i and j are closer than αt (Rti − Rtj ) then a force is applied to push them apart. For an
impregnable boundary, the force is only applied to the particle.

Fov (σi , σj ) = (αt |Rti + Rtj | − d(σi , σj )),
(2.2)
d(σi , σj ) < αt |Rti + Rtj |
where Rti is the designated radius of particle i based on its type t(σi ). αt is termed the
shoving factor and it determines the average packing density of particles of size Rti and Rtj .
Additionally, nearby particles experience attractive forces due to adhesion and surrounding
ECM. This is represented as potential function applied when d(σi , σj ) is greater than or
equal αt |Rti + Rtj |. Initially attractive forces increase from zero then fall off to zero as the
particle separate. The potential function in this case is a generalized Morse function [81].
Pairwise particle interactions can be associated or disassociated. Associated interactions model tight junction among cells of the ductal epithelium, the basement membrane,
and the extracellular matrix crosslinks. Here the particle’s neighbors are initialized and do
not change as particles move, creating a tight mesh that models the basement membrane,
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between epithelial cells, and in crosslinked stiff ECM. In contrast, disassociated particles
recompute their neighbors at each relaxation iteration before aggregate force calculation. In
this way, the attractive forces among disassociated particles drops off as they are separated
through movement, enabling displacement and separation by other particles as in the case
of growth, invasion, or ductal breach.

Mechanical Stress Fields
The particle forces mechanism described above is insufficient for capturing and resolving
all the movements in our simulation when ECM stiffens in response to the formation of new
cross-links due to LOX or weakens due to MMP. While particle shoving is a local level
interaction sufficient to model simple particle growth and division, a global mechanism is
needed to compute the movements imposed both by tightly linked particles and by particle
shrinkage that occurs in the modeling framework. Mechanical stress fields, increased by cell
linking and growth, and decreased by cell shrinkage or death, are used to apply movement
vectors to particles move them toward the locations as the stress is relaxed. This pressure,
termed “biomass pressure,” is expressed as the following elliptic differential equation [82],
[83]:

−5·



k
µ

5P



=

Pn

1 dMi
i=1 ρi dt

where P is the pressure generated from the growth or loss of biomass,

(2.3)
dMi
dt

is the local

biomass production or loss rate, ρ is the density, and the summation is iterated over all n
biomass types present in the model. This second order elliptic partial differential equation
specifies that the gradient of pressure transport is proportional to rate of volume production
or decay at each grid point. This equation is solved in our simulation by a semi-mulitigrid
equation solver to relax the pressure to a quasi stable state. Computing the pressure
gradient and applying the movement vectors is performed before applying the shoving.
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Figure 2.3. Extracellular Matrix formation as crosslinks between ECM particles (spheres
in the figure).

Extracellular Cellular Matrix
We model the ECM using a hybrid of discrete and continuous models. The discrete
component is as an organization of particles interacting with each other as described above.
The density, adhesion strength and particle interactions of this group specifies the emergent
properties of the formed matrix; particles do not represent the matrix directly, but rather
the cross-links between fibers (see Figure 2.3). The density of the links and their pair-wise
interaction responses indirectly determine the stiffness of the tissue-scale ECM.
The continuum component of ECM, introduced by Alpkvist et al. [82], models the local
secretion and accretion of ECM proteins as a local diffusion process. ECM is secreted from
one particle to accrete on a neighboring particle to form fiborious crosslinks (bonds between
particles).
ECM degradation occurs when MMPs reduce the stiffness of the ECM, weakening
bonds between particles and ultimately causing the particle's disappearance. This process
is modeled by reducing the mass of ECM particles proportional to the amount of MMP in
the microenvironment, and removing ECM and the associated crosslinks if their mass falls
below a threshold [84]. An example of this process is illustrated in Figure 2.4 along with
the reciprocal process of ECM stiffening caused by secretion of LOX.
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(a)

(b)
Figure 2.4. (a) ECM stiffening viewed over time(earlier to later is left to right). Blue
particles are secreting stiffening enzyme (LOX) that increases amount of ECM (spheres)
and cross links between ECM particles, causing the ECM to stiffen; (b) ECM degradation.
Red particles are secreting MMPs that degrade the surrounding fibers.

2.4.2

Ductal Carcinoma Model

This model incorporates the primary processes in ECM remodeling during the progression of DCIS to IDC described in Section 2.3. Figure 2.5 represents breast duct microarchitecture in cross-section in the initial state of the model. The duct is a tubular arrangement
of epithelial cells (pink particles), surrounded by myoepithelial cells (yellow particles) and
the basement membrane (small black linked particle forming a tight mesh). The initialing
tumor cell (TC) is the single blue particle positioned on the internal duct surface. Surrounding and supporting the duct is the stroma consisting of: ECM (the small light gray
particles) that contains fibroblasts (big gray particles) and myofibroblasts (cyan particles).
The stroma also contains blood vessels (red particles) that supply the duct with nutrients,
oxygen, and growth factors through the basement membrane.
In addition to different cell types, the model includes three diffusible biochemical factors
that determine cellular and ECM properties important for DCIS progression. Figure 2.6
illustrates an overview of the model components and their interactions. The model considers
two broad spatial domains: the region within the duct that contains epithelial cells and
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Blood vessel
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Stiff ECM
Fibroblast

Myofibroblast
Basement membrane

Myoepithelial
Epithelial (associated)

Epithelial (disassociated)
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Figure 2.5. The initial condition of the DCIS to IDC simulation. The duct is a tubular
arrangement of epithelial cells, surrounded by basement membrane and myoepithelial cells.
The duct is embedded within stroma that includes: ECM, fibroblasts and blood vessels
cells. There is a single tumor cell on the internal wall of the duct.

tumor cells and the stroma that contain the ECM and all other cell types. Tumor cells
produce MMPs (many forms of MMP aggregated by the model as a single class) that act
on the basement membrane and that can diffuse into the stroma.
In the basal state prior to DCIS, the rate of TGF-β production, a central regulator
of normal cell proliferation, is controlled, and ECM stiffening and degradation are in balance. When ductal tumor cells begin to proliferate, they cause activation of latent TGF-β
trigger by the increased MMPs production by the tumor cells [68, 85]. The increased activity of TGF-β in the stroma stimulates differentiation of fibroblasts into myofibroblasts
(Figure 2.6). Fibroblasts and myofibroblasts produce local ECM components at a constant
rate. Additionally, myofibroblasts secrete LOX that stiffens the ECM [86] .
In the model, MMPs are degrade the ECM and MMPs are over produced by malignant
epithelial cells. MMPs secretion is up-regulated by mechanical stress experienced locally by
each cell due to the ECM stiffening and tumor growth. The secreted MMP transforms the
basement membrane from a tight association with epithelial cells to being dissociated from
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Figure 2.6. The diagram represents the overview of inhibition and activation reactions and
the coupling among biomechanical and biochemical model components. The blue rectangles
represent cell/ECM types, the pink circles represent the soluble factors, the orange circle
represents the biomechanical stress(pressure), and the green circle represents the nutrient.
The arrows show whether the influence is either inhibitory or activating. The red arrows
represent the transitions between cells types that is regulated by a factor. For example, the
red arrow from fibroblast to myofibroblast signifies that this cell type transition is regulated
by TGF-β.

epithelial cells. MMPs weaken cross links between the ECM and ECs particles and causes
transformation from associated ECs to disassociated ECs. LOX initiates the covalent crosslinking of collagen and the elastin, increasing the tensile strength (stiffness) of the ECM
modeled the addition of particle links. The model, we assumed that the LOX is secreted
only by myofibroblasts after their differentiation from fibroblasts [87].
In the following model equations, all soluble factors are denoted Si , cell and ECM mass
is denoted Mi , Di represents diffusion rate, and µi represents maximum specific rate, where
i denotes for cell or particle type. See Table 2.1 for a summary of model parameters.
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Nutrient (oxygen) Secretion
The model considers that nutrients are secreted by capillary endothelial cells of capillaries (Mbc ) and consumed by tumor cells (Mtc ) based on the following equation:
∂Sn
= DSn 52 Sn + µSn Mbc − µScn Mtc
∂t

(2.4)

In this equation, DSn is the nutrients diffusion coefficient, µSn is the maximum specific
rate of nutrients secretion (units of 1/hour), µScn is the maximum specific rate of the
nutrient consumation (units of 1/hour), and Mtc is the mass of tumor cells.

Tumor Growth
The tumor growth is activated by nutrients supplied by blood vessels, and downregulated by mechanical pressure effects according to Equation 2.5.
Sn
Ktc
∂M tc
= µtc
Mtc
∂t
Sn + Kn P + Ktc

(2.5)

Here, µtc is the maximum specific rate of tumor growth (units of 1/hour), and Mtc is
the mass of tumor cells. Note that pressure down-regulates growth (shown in Figure 2.6).

MMP Secretion
The model includes the influence of increasing mechanical stress (represented by pressure P ) on the up-regulation of MMP secretion as shown in equation 2.6.
∂Sm
P
= DSm 52 Sm + µSm
Mtc
∂t
Km + P

(2.6)

Here, DSm is MMP diffusion coefficient, P is the pressure that affects the cell, µSm is
the maximum rate of MMP secretion ( units of 1/hour,) and Mtc is the mass of the tumor
cell.
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TGF-β Secretion
TGF-β is a protein that controls cellular proliferation, and differentiation. The TGF-β
exists in a latent, ECM-bound form that is converted to an active, diffusible form of TGF-B
according to Equation 2.7 .
∂Stg
Sm
= DStg 52 Stg + µStg
Me
∂t
Kt g + Sm

(2.7)

Here DStg is the active form TGF-β diffusion coefficient, µStg is the maximum rate of
the TGF-β release (units of 1/hour), and Me is the mass of ECM. TGF-β is converted from
a latent to an active form when the MMPs concentration exceeds a threshold [68].

LOX Secretion
LOX is an amine oxidase that plays a critical role in the biogenesis of connective tissue
matrices by cross-linking, collagen and elastin in the ECM. The LOX is secreted in the
stroma by myofibroblasts based on Equation 2.8.
∂Sl
= DSl 52 Sl + µSl Mmc
∂t

(2.8)

In this equation, DSl is the LOX diffusion coefficient, µSl is the maximum rate of the
LOX secretion (units of 1/hour), and Mmc is the mass of myofibroblasts.

ECM Protein Secretion
The model considers that ECM proteins are synthesized by fibroblasts and myofibroblasts according to the following equation:
∂Se
= DSe 52 Se + µSem Mmc + µSef Mf c
∂t

(2.9)

Here, DSe is the ECM protein diffusion coefficient, µSem is the maximum secretion
rate of ECM protein secretion by myofibroblasts (in units of 1/hour). µSef is the maximum
secretion rate of ECM protein secretion by fibroblasts (units of 1/hour). Mmc is the mass
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of myofibroblasts, and Mf c is the mass of fibroblasts. We assumed that ECM proteins are
secreted at constant rate by both myofibroblasts and fibroblasts and that ECM protein
secretion rate by myofibroblasts is greater than by fibroblasts.

ECM Degradation and Accretion
The ECM is degraded by MMPs based on equation 2.10 .
Sm
∂Me
Me + µSe Se
= −µM e
∂t
K m + Sm

(2.10)

In this equation, µM e is the maximum ECM degradation, Me is the mass of ECM, Sm
is the MMP concentration, and µSe is the accretion rate at which the soluble ECM proteins
are incorporated into the insoluble ECM.

Mechanical Stress
As the right-hand side of Equation 2.3 shows, the changes in the rate of volume increase
alter the pressure fields. In the progression of DCIS to IDC, tumor growth, ECM decay,
and production and remodeling are the main sources of volume changes. If the right part
of Equation 2.3 is rewritten using these terms, new equation can be written that is tailored
for this model:

− 5 · (λ 5 P ) =

1 ∂Mtc
ρtc ∂t

+

1 ∂Me
ρe ∂t

(2.11)

where ρtc and ρe are the spatial density distributions of tumor cells and the ECM, respectively. This equation reflect the activity of the feedback loops seen in Figure 2.6. Crosslinking and cells growth increase pressure while cell shrinkage or death decrease pressure.
Table 2.2 summarizes the reactions in each type of cell and ECM used in the model.
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(A)

(B)

(C)

(D)

(E)

Figure 2.7. The stages from a normal duct into an invasive tumor during simulation. (A)
The initial condition for DCIS at iteration 2. (B) The growing tumor triggers the activation
of TGF-β that promotes differentiation of fibroblasts into myofibroblasts at iteration 100.
(C) Newly differentiated myofibroblasts secrete LOX that begins stiffening the ECM with
additional cross-linking and accretion. The ductal wall integrity at the location of tumor
initiation has been compromised, but tumor cells are still contained within the duct at
iteration 130. (D) The tumor cells have filled the duct, broken through the ductal wall and
begun invasion of the surrounding stroma at iteration 180. (E) The duct is so weakened
that multiple breaches have occurred and tumor cells have invaded throughout the stroma
at iteration 215.

2.5

Results
In this study, we execute the model of the progression of DCIS to IDC, starting from

the initial condition of single cancerous cell in a mammary duct as shown in Figure 2.5.
Once known parameters were set from the literature (see Table 2.4), the few remaining
parameters were estimated and refined by evaluating the ability of the model to recapitulate
tumor progression.
Five studies were performed:
1. The fidelity of the tissue-scale behavior of the simulation was evaluated by comparing
the sequence of events that emerge in running the model with the sequence of events
that unfold in the progression of DCIS to IDC.
2. Interactions that weaken ductal integrity were studied to understand how tumor
growth-driven biomechanical stress leads to MMP secretion and subsequent epithelial
tight-junction and basement membrane degradation.

32

L2
L1
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Figure 2.8. Simulated microdissection sites around the duct where biochemical concentrations and biomechanical forces are quantified. L1 is the point of tumor initiation.

3. The effects of stromal stiffening due to TGF-β activation, fibroblast differentiation,
LOX secretion and ECM cross linking were explored.
4. The growth of tumor and stromal cells were studied to understand their effect on
breach of the duct basement membrane.
5. Micrographs of ductal tissue during progression from DCIS to IDC were compared to
the model output.

2.5.1

Emergence of DCIS Progression to IDC Developmental Stages / Emergence Stages of DCIS Progression to IDC

The simulator is initialized at a state of health breast duct microarchitecture, as shown
in Figure 2.5. The initial location of the tumor cell is specified randomly. We identify
five stages of progression to IDC that occure at iteration 2, 100, 130, 180, and 215 (see
Figure 2.7). These are: (A) TCs start growing, consuming nutrients and produceing higher
amounts of MMP due in response to biomechanical stress, converts TGF-β into active
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TGF-β, as shown in Figure 2.7 (A). (B) The active TGF-β within the ECM promotes
the differentiation of fibroblasts into myofibroblasts, shown in Figure 2.7 (B). (C) The
myofibroblasts begin secreting LOX that in turn induces collagen cross-linking and stiffens
ECM, shown as small dark gray particles in Figure 2.7. (D) A feedback loop between
the stroma and ECs is formed, where tumor growth combined with the stiffening-ECM
heightens the compressive and tensile forces on the duct. The increasing pressure promotes
ECs and TCs to secrete yet more MMP to bring the tissue back to homeostasis. The
increased MMPs degrade more ECM and weaken the junctions between epithelial cells and
basement membrane particles, as shown in Figure 2.7 (D). (E) As a result, the TCs breach
the basement membrane and initiate invasion of the surrounding stroma (Figure 2.7 (E)).

2.5.2

Biomechanical Stress and MMP Effects on Ductal Integrity

We monitored the spatial distribution of biomechanical stress (referred to as tissue
pressure) and MMP concentration, illustrated in Figure 2.9 A through E. In the early stage
of tumor growth, a small amount of MMP is secreted by TCs, while tumor growth produces
a local region of pressure centered on the site of tumor initiation. The pressure prompts the
TCs to increase their MMPs secretion. The increased MMP weakens the junctions between
EC particles and the basement membrane, and degrades the ECM. In addition, the pressure
inside the duct builds, causing the TCs to push against the basement membrane. The
increased pressure inside the duct, and the weakened junctions between epithelial cells and
the basement membrane causes tumor cells to breach the basement membrane and escape
within stroma.
The model indicates a significant pressure relief within the duct as multiple breach
points occur and tumor cells disperse through the surrounding stromal tissue, as illustrated
in Figure 2.9 stage E. This intra-ductal pressure relief is countered by a significant increase in pressure in the surrounding stroma that can lead to increased MMP secretion and
subsequent ECM weakening, further promoting invasion.
The pressure and MMP concentration is illustrated in Figure 2.10 at the locations
around the duct shown in Figure 2.8. Figure 2.10 illustrates how the evolution of pressure
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Figure 2.9. Spatial distributions of pressure and MMP in different simulation iterations
(iteration 2, iteration 100, iteration 130,180, and iteration 215, respectively) along with the
corresponding morphology. Red indicates a high value, blue a low value.

and MMP concentration in the surrounding stroma varies by location. We noted that the
region near the growing tumor has the highest pressure and MMP concentration where the
breach occurs. We observed that the pressure increases at L1 until about iteration 130,
when pressure decreases within the duct after release of stress into the stroma due to the
breach of duct basement membrane. In contrast, at L2, a stromal location near the breach
point, and at L3, a stromal location opposite the break point, the pressure rapidly increases
following the breach. The simulation indicates that pressure at breach points is highest,
the pressure is relaxed after breach of the basement membrane, and the breach point occurs
near the site of the initial tumor cells.
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Figure 2.10. Pressure and MMP levels as a function of model iteration in the different
locations in the duct given in Figure 2.8.

2.5.3

TGF-β and LOX Effects on Stromal Stiffening

We investigated the biomechanical and biochemical mechanisms that lead to stiffening
of the ECM. Figure 2.11 shows the spatial distribution of active TGF-β, which triggers
fibroblast-to-myofibroblast differentiation, and the concentration of LOX, which stiffens the
ECM. In an early stage, at iteration 2, a high level of active TGF-β appears at the tumor
initiation site. This is due to increased MMP secretion. At this early stage, the TGF-β
concentration in the ECM is still low and insufficient to prompt fibroblast differentiation.
The LOX concentration is also very low since there no myofibroblasts, the source of LOX,
in the stroma. By iteration 100, these has been sufficient tumor growth to secret a high
amount of MMP. This triggers the conversion of latent TGF-β into active TGF-β. This
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Figure 2.11. Spatial distribution of TGF-β and LOX as the simulation progresses.

active TGF-β triggers the differentiation of fibroblast cells into myofibroblasts in iterations
130. Subsequently, LOX is secreted by myofibroblasts and diffuses into the stroma, crosslinking and thereby a stiffening the ECM. The model indicates that, TGF-β and LOX work
to modulate the microenvironment in a way that promotes the early stages of metastasis.
Disrupting the cross talk between TGF-B and LOX may offer a target to slow or prevent
the DCIS to IDC transition.
Figure 2.12 illustrates TGF-β and LOX concentration at different locations around the
duct (see Figure 2.8). The distribution of TGF-β is nearly uniform throughout the stroma
due to its high diffusibility. LOX on the other hand has low diffusibility and is mostly
locally concentrated around the recently differentiated myofibroblasts. The reduction in
LOX around the breach point following the breach event is due to the ECM being displaced
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Figure 2.12. TGF-β and LOX concentrations as a function of iteration in different locations
in the duct.

by the invading tumor cells.

2.5.4

Cell Population Dynamics

The number of TCs, myofibroblasts, and TCs were monitored over the course of the
simulation to understand cell population dynamics in the transition from DCIS to IDC. The
upper panel of Figure 2.13 shows the number of tumor cells over the course of the simulation.
It illustrates that the number of tumor cells increases exponentially during the initial stages
when the cells are confined to the duct. However, as the duct fills and the cells become
invasive, the growth rate slows due to increasing stromal pressure. The differentiation of
fibroblasts into myofibroblasts takes place relatively quickly and is completed when the duct
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A
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C

Figure 2.13. The number of TCs, myofibroblasts, and TCs outside the duct as a function
of iteration.

is filled with TCs.

2.5.5

Fidelity of the tumor growth model

We compared the model simulation of the normal non-cancerous breast duct with a
micrograph of normal duct, and did a similar comparison at the transition to IDC during
ductal breach with an image of this stage in vivo. Figure 2.14 a micrograph of a normal
duct with the corresponding initial state of the model. The normal breast duct shown in
the micrograph and at the initial stage of the model are very similar.
Figure 2.15 shows the early stage of IDC as the basement membrane is being breached
in a mammary duct and as simulated in the model. Once again, at this level of observation,
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Micrograph Image

Simulation

Figure 2.14. The architectural relationship of the basement membrane, myoepithelial cells,
and epithelial cells of ducts in a normal human mammary gland. The left one is micrograph
image where the arrow identifies the basement membrane (brown), the arrowhead designates
a ME cell (red) [5]. The right one is simulation image where the bold arrow identifies the
basement membrane (black) and the thin arrow designates myoepithelial cell (yallow).

the agreement is good between the model and the actual progressing cancer in the mammary
duct.

2.6

Conclusions
In summary, we developed a 2D agent-based model of the development of ductal car-

cinoma in situ and its progression to invasive ductal carcinoma. This model is different
from the majority of computational models of breast cancer in its explicit consideration of
biomechanicala forces in addtion to the activities of biochemical agents.
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Micrograph Image

Simulation

Figure 2.15. Disruption of the myoepithelial cells layer and breach of the basement membrane are prerequisites for invasion. The myoepithelial cell layer and basement membrane
in one duct is locally disrupted and the epithelial cells are in direct contact with the stroma
(an arrow) [5].

The model supports the idea that the interaction between tumor cells in the duct and
the surrounding stroma plays a critical role in tumor growth and invasion of tissues outside
the duct. Many mechanical and chemical factors work together to allow invasion. This
work may provide a system with a robust predictive modeling and visualization to aid in
the discovery of mechanisms of tumorigenensis and the earliest stages of metastasis, and
the rapid testing of candidate therapeutics approaches.
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2.7

Appendix
Table 2.1. List of parameters symbol description
Symbol
Mmc
Mf c
Mtc
Me
Mbc
Sn
Sm
Stg
Sl
Se
DSe
DSm
DSl
DSn
DStg
µSem
µSef
µSm
µSl
µM e
µSn
µStg
µM tc
KS

Description
Biomass of myofibroblasts
Biomass of fibroblasts
Biomass of tumor cell
Biomass of ECM
Biomass of blood vessels
Nutrients soluble factor
MMP soluble factor
TGF-β soluble factor
LOX soluble factor
ECM soluble factor
ECM proteins solute diffusion coefficient
MMP soluble factor diffusion coefficient
LOX soluble factor diffusion coefficient
Nutrients soluble factor diffusion coefficient
TGF-β soluble factor diffusion coefficient
Maximum specific rate for ECM secreation by myofibroblast
Maximum specific rate for ECM secreation by fibroblasts
Maximum specific rate for MMP secretion reaction
Maximum specific rate for LOX secretion reaction
Maximum specific rate for ECM degradation reaction
Maximum specific rate for nutrients secretion reaction
Maximum specific rate for TGF-β secretion reaction
Maximum specific rate for tumor cell growth reaction
half-maximum concentrations parameter where S denoted soluble factor/biomass type

Table 2.2. List of Equations number per cell type
Cell \ ECM Type
Tumor Cell
MyoFibroblast
Fibroblasts
Blood Vessel
ECM

Equations number
2.6 , 2.5
2.8 , 2.9
2.9
2.4
2.10 , 2.7
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Table 2.3. List of soluble factor per cell type
Secreted soluble Factor
MMP
LOX
Continuous ECM protin
Nutrients
TGF-β

Variables
Sm
Sl
Se
Sn
Stg

Table 2.4. In Vitro Parameters for DCIS Model
Parameter
Epithelial cell radius
Myoepithelial cell radius
Tumor Cell Radius
Production rate of TGF-β from TCs
TGF-β Diffusion Coefficient
Oxygen Diffusion Coefficient
MMP Diffusion Coefficient

Explanation
0.5
0.25
9.953 um
1.72 × 10−9 s−1
1.8 × 10−7 cm2 s−1
1.55 × 10−4 m2 day −1
1 × 10−6 cm2 s−1

Value
[63]
[63]
[65]
[88]
[89]
[64]
[64]

Refs.
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CHAPTER 3
DEVELOPING AN IN SILICO MODEL TO STUDY THE
EFFECT OF RETINAL PIGMENT EPITHELIAL CELL
PATCH SIZE ON VEGF PRODUCTION

3.1

Abstract
The spatial organization and growth of retinal pigment epithelial (RPE) cells is a

vital process in the progress of age-related macular degeneration (AMD). While in vitro
experiments provide models for replicating disease states associated with the deterioration
of retinal tissue during AMD, the progression and behaviors of RPE cells in AMD and
the stimuli leading to the enhanced secretion of the central driver of AMD progression,
vascular endothelial growth factor (VEGF) from RPE cells are not fully understood. In
addition, in vitro culture methods are generally expensive and time-consuming. In this
study, an in silico model was developed to provide a framework used for understanding
the underlying mechanism of VEGF production, predicting the VEGF produced by each
cellin colonies (patches) of different sizes, and analyzing the effect of a VEGF agonist.
We also present experimental validation of the simulated results and predict the spatial
distribution of VEGF produced by cells in different sized patches. This model may provide
a system with robust predictive modeling and visualization that could enable discovery of the
molecular mechanisms involved in AMD progression and provide routers to the development
of effective treatments.
0
The coauthors for this chapter are: Qanita Bani Baker, Gregory J. Podgorski, Elizabeth Vargis, and
Nicholas S. Flann
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3.2

Introduction
Age-related macular degeneration (AMD) is a leading cause of irreversible blindness,

particularly among adults over age 50 [44,45,90]. Degeneration of retinal pigment epithelial
(RPE) cells severely damages the visual function of retina photoreceptors. In AMD, new
blood vessels from the underlying choriocapillaris disruptively invades the retina [91]. Vascular Endothelial Growth Factor (VEGF) is the primary growth factor in angiogenesis [92]
and an important biomarker of AMD [93]. In the retina, VEGF is secreted in the RPE and
is mainly responsible for retinal vasculature development [94,95]. In vitro models that allow
controlling the spatial organization and growth of RPE cells can provide important tools for
understanding cell behavior in AMD processes. Monitoring the expression of VEGF within
the controlled environments of these model systems can lead to new insights that improve
our understanding of how AMD is initiated and developed over time.
In the cell culture model of AMD that is the focus of this work, micropatterning
techniques are used to restrict the location and shape of the substrate regions on which
cells attach [96–98]. The impact of micropatterning on cellular functions and morphologies
has been investigated with many types of cells including fibroblasts [99], neuronal cells [100],
retinal pigment epithelial cells [1,101–104], stem cells [105], epithelial cells [106], and cancer
cells [107]. Vargis et al. [1] used micropatterned surfaces to control the spatial organization
of RPE cells in Figure 3.1 to explore how atrophy, loss-of-function, or tissue damage within
the retina affect VEGF production. While cell culture provides a model for replicating
disease states associated with the deterioration of retinal tissue during AMD, the stimuli
leading to enhanced VEGF secreted from RPE cells and the subsequent neovascularization
processes in the choroid are still not fully understood [48, 49], and little is known about the
VEGF regulation in the eye [95]. In addition, little is known about the drugs’ mechanisms of
action, how and why several diseases such as AMD become resistant to the treatment, or the
types of patients that can benefit most from these drugs [108]. Computational approaches
combined with in vitro experimental studies can shed light on these issues by providing a
framework for generating and testing hypotheses related to VEGF regulation and transport
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Figure 3.1. Micropatterning method used in [1]. Substrate functionalization and cell seeding
are accomplished by molding a PDMS stamp from an etched silicon master as in steps (a,
and b). Then, the stamp is inked using a fibronectin solution, allowed to dry and then
placed in contact with a polystyrene or glass culture dish as in steps(c-f). After that, the
surface is blocked with Pluornic prior to seeding RPE cells onto the fibronectin-patterned
substrate as in steps (g, and h).

in the tissue retina [109].
Developing an in silico framework for the in vitro cell patterning model provides a
system that could be extremely useful in evaluating the temporal-spatial effects of VEGF
transport and expression within these controlled environments, and in replicating the disease
state to gain new insights on disease progression and outcomes. It also can be used to
study internal and external regulatory mechanisms influenced by feedback from the evolving
cellular environment. Developing this predictive model is essential to improve understanding
and generate new hypotheses that may be used in the development of pharmaceutical agents.
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The goal of this study was to develop an in silico model to replicate and extend cell
microprinting model for AMD reported in [1]. Using this model, we studied the growth of
RPE cells in discrete patches and measure the effect of patch size on VEGF expression. The
VEGF level in each patch is studied as a function of cell number and patch area over time.
To study the hypothesis that VEGF expression is linked to global VEGF concentration in
culture, VEGF expression from various size patches was quantified following VEGF agonist
administration. This study complements experiments performed in vitro and provides a
framework that can be used to study the influence of cell patterning on the secretion of
VEGF by the RPE tissue, and opens a path towards mimicking the effects of tissue damage
or atrophy in tissue engineering. This model is applied to extend the study of Vargis et
al [1] and to make new predictions. The in silico model may be used to examine the
effects of anti-VEGF agents that potentially can aid in the optimization of anti-angiogenic
therapeutics.

3.3

Materials and Methods

3.3.1

In vitro methods

The bioengineered micropatterning techniques are used to create a regular arrangement of circular colonies, called patches, populated with RPE cells surrounded by a empty
substrate as shown in [1]. Creation of this micropatterns involves multiple sequential steps
as shown in Figure 3.1. The non-populated regions imitate necrotic regions in the retina
that result from repeated exposure to reactive oxidative species, triggering death of the
retinal pigment epithelium followed by death of the overlying photoreceptors and neovascularization, leading exudative AMD [50, 51]. Recreating these regular spatially-organized
cellular configurations helps to isolate the impact that local cell-cell and cell-environment
interactions have on VEGF expression.
In the experimental study, described in [1], stamps with patches of 100 µm, 200 µm,
300 µm, and 400 µm were employed to vary the mix of cell-cell and cell-environment in
each experiment. Each patch was seeded with retinal pigment epithelial cells and grown in
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a cellular culture. VEGF per cell was measured at regular intervals: 4, 24, 30 48, 54, and 72
h after cells seeding and reported in pg/ml. To measure the VEGF per cell, the total VEGF
contained within the cell culture was determined using enzyme-linked immunosorbent assay
(human VEGF ELISA kit), and the number of cells per patch was determined using image
analysis proceeded by staining. Figure 4.1(a) (taken from [1]) illustrates the stained patches
at 72 h. The experiments were repeated at least ten times and averaged. The final spatialtemporal data obtained are illustrated in Figure 4.1(b). The final spatial-temporal data
obtained after adding the VEGF agonist are illustrated in Figure 4.1(c)
A VEGF agonist was also added to the patterned surfaces at a concentration of 5
ng/mL after 20 h in culture, in order to determine if the higher levels of VEGF expression
observed in cells grown in small patches was the result of cells responding to lower initial
overall levels of VEGF in the RPE microenvironment. VEGF expression was also measured
before the addition of the VEGF agonist (at 4 h) and after the addition at (24, 30 48, 54,
and 72 h). The final spatial-temporal data produced are illustrated in Figure 4.1(c).

3.3.2

Hybrid Agent-Based Model Framework

In silico computer-based modeling has proved its effectiveness in several biological research studies [110]. In silico models, especially agent-cell-based models, can bridge in vitro
and in vivo experiments since they can integrate measurements from several in vitro experiments, reconstruct certain aspects of in vivo environments, and provide the capabilities for
a systematic analysis of the influence of individual as well as combined factors on full-scale
biological system behavior [111]. To simulate the RPE cell growth in several patch sizes,
we extend the agent-based modeling framework developed by the Kreft group at University
of Birmingham, called iDynoMiCs [55].
In this framework, we have two main components: particles and soluble products,
integrated within a reaction diffusion system. Particles represent individual cells that mechanically interact, secrete, consume or react to soluble products. They are positioned in
space and occupy the volume of a single cell. Soluble product distributions make up the
continuous component of the system and are determined by a diffusion solver which resolves
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(a)

(b)

(c)
Figure 3.2. The result as shown in the experiments performed by Vargis et al. in [1] (a)
Patches of stained RPE cells at 72 h for each patch size. [1]. (b) Time course of VEGF
expression per cell measured at 4, 24, 30, 48, and 72 h as in [1]. (c) Time course of VEGF
expression per cell measured before the addition of the VEGF agonist(at 4 h) and after (24,
30, 48, 54, 72 h) [1].

all the local changes in concentration induced by the particle and long range diffusion. In
the simulation, it is assumed that the soluble product fields are in steady-state with respect
to cell mechanisms since solute reaction and diffusion occur on the order of seconds, while
cell mechanisms occur on the order of hours to days.
Reactions drive growth to increase the biomass of a particle. As the biomass increases
so does the particle radius, based on the cubic root of the volume. When the radius equals
or exceeds a maximum state-specific particle size parameter called the split radius Rsp in
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units µm, the particle is divided into two particles along a random cleavage plane, such that
the sum of the volumes of the new particles approximately equals the specified maximum
volume. The two smaller particles are positioned without mutual overlap in the place of
the parent particle. Any overlap with neighboring cells is ignored during placement and
resolved during force relaxation. Particle size can be reduced through biochemical reactions
that cause biomass consumption, decay, particle apoptosis, or necrosis. When the radius
equals or falls below the minimum particle size parameter, called the death radius Rd in
units µm, the particle is removed from the domain. This framework is explained in more
detail in the Supporting Information section.
In this model, it is assumed that the boundary conditions are cyclic for the sides of
the 2D domain. Cyclic boundaries allow simulation of larger domains by assuming that the
computation domain region is replicated indefinitely. The two connected boundaries are
specified together when creating cyclic boundary conditions. Solute concentrations are kept
constant across cyclic boundaries, and any agent crossing one of the cyclic boundaries will
be instantly moved to the connected boundary.

3.3.3

In silico model for RPE growth in several in vitro patch sizes

The bioengineered experiments are simulated using the hybrid agent-based approach.
The setup of the simulations replicates the same experimental conditions and units as in
the in vitro experiments. The domain size of each simulation is 2400 µm, initial cell size is
set to 80µm2 , and 36 h is the doubling time due to growth. Each simulation begins with
multiple RPE cells distributed at the reported patterning efficiency (cell density) in several
patches arranged in the specific experimental pattern. The simulation replicates the first
72 h of the in vitro experiments. The initial conditions for different patches are shown in
Figure 3.3. Illustrations of the simulated experiments, after 72 h, are shown in Figure 4.2.
The autoregulation of VEGF secretion as a function of biomass M and local VEGF
concentration V is described using Equation 4.1. The diffusion coefficient of VEGF DV is
set to 5.8 × 10−11 m2 s−1 , taken from microfluidic experiments described in [112]. As shown
from this Equation 4.1, VEGF expression is auto-regulated by negative feedback inhibition
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Table 3.1. Initial Number of Cells in Each Patch based on [1]
PatchSize
Patch 100
Patch 200
Patch 300
Patch 400
Patch 500

(A)

Initial Number of Cells.
15 Cells
74 Cells
189 Cells
351 Cells
612 Cells

(B)

(C)

(D)

Figure 3.3. Patch arrangement in the simulation. (A)Patch 100 µm, 12 paches in each side.
(B) Patch 200 µm, 6 paches in each side. (C) Patch 300 µm, 4 paches in each side. (D)
Patch 400 µm, 3 patches in each side.

loop via the amount of VEGF in the surrounding domain.
∂V
K
= DV 52 V + αV
M
∂t
βV + K

(3.1)

The equation after adding VEGF agonist will be as in Equation 3.2. This equation
assumed that the receptor singling for VEGF is the same for VRGF agonist. This suggest
that the cell may function to maintain a consistent level of VEGF and VEGF agonist within
their local environment.
∂V
K
= D(V +V a) 52 V + αV
M
∂t
β(V + V a) + K

(3.2)
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Over time, the RPE cells grow based on a doubling time of 36 h [113], which determines
the growth rate parameter µM . Since nutrient is unlimited and cell crowding is not an issue
within the 72 hour time line, we applied first order kinetics reaction for cell growth as shown
in Equation 4.2.
∂M
= µM M
∂t

(3.3)

Table 3.2 summarizes the description of the parameters used in the equations above
and identifies the known parameters and those that need to be determined by the method
developed in Chapter 4.
Table 3.2. Model’s parameter descriptions
Parameter
DV
µM
K
µV
β
Rsp

3.4

Value
−11

2 −1

5.8 × 10
m s
1.0194 hour−1
0.13
0.09
0.850
6.2996 µm

Description

Ref

Diffusion coefficient
Max. growth rate for RPE cells
Auto regulation rate
Secretion rate
Binding affinity
Cell Division Radius

[112]
[113]
Chapter 4
Chapter 4
Chapter 4
[1]

Results
In this study, we utilized the hybrid agent-based framework to model RPE cell growth

within different patches size setups. The in silico model was executed from the initial condition, shown in Figure 3.3, and assessed the simulated changes from the first hour to the
end of the experiments at hour 72. In this section, using the developed in silico model,
the VEGF concentration per cell was measured at various time intervals and after adding
a VEGF agonist to the patterned surfaces with several sizes. The visualization of VEGF
distribution in different patch sizes was also reported. This framework was also applied to
study a more realistic model of retinal degeneration when open areas with no living cells
develop in the retinal endothelium. Additionally, we used this model to study the effect of
VEGF agonist concentration on the final VEGF concentration per cell. Here, the concentration of VEGF per cell was measured after adding several VEGF agonist concentrations
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(a)

(b)

Figure 3.4. Comparing VEGF concentration per cell in vitro and in simulation. (a) The
left graph represents the data obtained in vitro from [1]. (b) The right graph represents the
data obtained from the simulation.

at the same time intervals as previous experiments.

VEGF concentration per cell
The total VEGF expression in the simulation was first calculated for each domain after
72 h and was reported as VEGF concentration per cell as shown in Figure 3.4 (b). In these
studies, the VEGF concentration per cell is inversely proportional to the patch size, i.e.
RPE cells in the smaller patches express higher levels of VEGF per cell. To validate the in
silico model, we compared the simulation results with the in vitro data from [1]. In both, 3.4
(a) and 3.4 (b), it is noted that the RPE cells in small patches express higher levels of VEGF
per cell. This indicates that these cells are auto-regulated VEGF to maintain a consistent
level of VEGF within their local microenvironment. Cells in smaller patches respond by
expressing higher amounts of VEGF to maintain basal VEGF levels, while RPE cells in
larger patches maintain the same basal levels of VEGF by expressing smaller amounts of
VEGF per cell.
To show how the concentration of VEGF changes over time in the simulation, VEGF
expression levels were also calculated at various time intervals (4, 24, 30, 48, 54, and 72
h) and reported as VEGF concentration per cell. As shown in Figure 3.5 (b), the level of
VEGF increased over time. At hour 4, VEGF concentration per cell was approximately
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(a)

(b)

Figure 3.5. Comparing the time course of VEGF expression per cell measured at 4, 24, 30,
48, and 72 h, different patch sizes (100 µm, 200 µm, 300 µm, and 400 µm), in vitro and in
simulation. (a) The left graph represents the data obtained in vitro from [1]. (b) The right
graph represents the data obtained from the simulation.

the same for all patche sizes. However, significant differences were observed after hour 48,
where smaller patches produced a higher amount of VEGF than larger patches. In both 3.4
(a) and 3.4 (B), it is noted that the RPE cells in small patches expressed higher levels of
VEGF per cell than the larger patches. This confirms that cells growing in small patches
may experience different local concentrations of VEGF compared to cells in larger patches.

VEGF concentration per cell with VEGF agonist
To determine if the higher levels of VEGF expression observed in cells grown in small
patches are the result of cells responding to lower initial overall levels of VEGF in the
RPE cells microenvironment, the VEGF agonist was added to the patches 20 h after the
initial cell seeding, at a concentration of 5 ng/ml based in both in vitro experiments and in
silico simulations. In the in silico VEGF agonist V a is auto-regulated based on Equation
3.2. Then the concentration of VEGF per cell after the addition of the VEGF agonist was
calculated at the same intervals as previous experiments and reported as the change in
VEGF expression per cell for each patch size.
In both the in vitro and in silico, as shown in 3.6 (a) and 3.6 (b), respectively, adding
the VEGF agonist effectively increased the amount of VEGF detected by the cultured cells
in each sample. In both the in vitro culture and the simulation, the VEGF levels per cell
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(a)

(b)

Figure 3.6. In vitro and simulated effects of the VEGF agonist addition on VEGF expression. The agonist was added after 20 h of culture. (a) Data obtained in vitro. (b) Results
of the simulation.

obtained from smaller patch sizes (100, 200, 300 µm) decreased after the VEGF agonist
was added. This confirms the hypothesis that cells within these smaller patches reduce
VEGF expression levels because of the increased levels of VEGF detected within their local
environment. The patches of larger sizes (400 µm) were already exposed to higher levels of
VEGF; hence they showed small changes in expression levels after the addition the VEGF
agonist.

VEGF Distribution
Using the in silico model, we monitored the spatial distribution of VEGF in the different
patches. Simultaneous VEGF concentration profile is evoluted using the in silico models.
Figure 3.7 shows the VEGF distribution profile in 2400 µm X 2400 µm area for different
patch sizes 100 µm, 200 µm, 300 µm, and 400 µm). This insight gained by the model
observations, cannot be made experimentally either through in vitro or in vivo models.
The results indicate that VEGF distribution in tissues increased gradually over a specific period. This also suggest that patterning efficiency and detailed quantitative distribution of VEGF could be another factors that are worth to study their effects in the disease
progression.
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(1h)

(4h)

(24h)

(48h)

(54h)

(72h)

(Patch 400)

(Patch 300)

(Patch 200)

(Patch 100)
Figure 3.7. Simultaneous evolution of the VEGF distribution profile in 2400 micrometers
area for different patches size.

Prediction
The ultimate goal of any modeling effort is to provide actionable predictions [34]. Ideally, important experiments that could not be performed in vitro could instead be done
using the developed in silico approach. For instance, a more realistic model of retinal degeneration is one in which open areas with no living cells develop in the retinal endothelium.
This can be modeled using a similar arrangement of patches, but where the cells are applied to the areas outside of the disks, which are left empty. The inverse distributions of the
cells (where cells is located outside the patches and all patches are empty) were modeled
and the effects of different sizes patches were simulated and studied through the developed
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framework.
To show how the concentration of VEGF changes over time in the simulation with
inverse distributions setup, VEGF expression levels were also calculated at various time
intervals (4, 24, 30, 48, 54, and 72 h) and reported as VEGF concentration per cell as
shown in Figure 3.10. The results got from this experiments suggest that this inverse setup
is not so informative, since the several patches’ sizes do not play a critical role in such
distribution.

3.5

Discussion
This study offers an in silico model that utilized a hybrid agent based framework

to model bioengineering in vitro experiments. The coupling between in silico models and
bioengineering laboratory works provide an effective strategy for mechanistic understanding
of mechanisms and interaction using spatial-temporal data. This coupling could help in
identifying key regulating parameters of the laboratory process and predicting the early
information in order to assess the systems’ and processes’ behaviors. We argue that using a
hybrid agent based framework for such system is adequate, since this framework is implicitly
include the spatiotemporal locality effects within the cell, or cell-cell interactions.
In vitro experiments provide a model for replicating disease states associated with the
deterioration of retinal tissue during age-related macular degeneration (AMD). To quantitatively interpret such experimental results, an in silico model can be beneficial and predictive.
In this study, in silico model was developed in order to replicate the in vitro experiments
in [1]. The setups of the in silico model imitate the same experimental conditions and units
as described in the in vitro works and predict the VEGF concentrations per cell in several
spatiotemporal conditions. The results obtained from the in silico model confirm that the
RPE cells in small patches expressed higher levels of VEGF per cell. This suggests that
these cells may function to maintain a consistent level of VEGF within their local microenvironment. Additionally, cells in smaller patches respond by expressing higher amounts of
VEGF to maintain VEGF levels. RPE cells in larger patches can maintain the same levels
of VEGF by expressing smaller amounts of VEGF per cell.
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(a)

(b)

(c)

(d)

Figure 3.8. (a) Closeup of initial condition of a 400 µm patch (b) Experiment with 400
µm, 3 patches in each side. (c) Closeup of the VEGF distribution after 72 h, (d) VEGF
distribution over whole domain after 72 h.

The developed in silico model is quantitatively validated based on the available experimental data. The model can provide quantitative interpretation of the in vitro data
and may be used in predicating the effects of further spatial cells distribution conditions.
In future work, we suggest to use a searching approach to find the patches organization
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(A)

(B)

(C)

(D)

Figure 3.9. Patch arrangement in the simulation. (A)Patch 100 µm, 12 patch in each side.
(B) Patch 200 µm, 6 paches in each side. (C) Patch 300 µm, 4 paches in each side. (D)
Patch 400 µm, 3 patches in each side.

Figure 3.10. VEGF expression per cell measured at 4, 24, 30, 48, and 72 h from the
simulation in inverse distributions of the cells as shown in Figure 3.9.

that identify the most informative configuration. This search will identify several spatial
cell organizations that may effectively mimic the effect of atrophy and loss-of-function that
occurs in the retina during degenerative diseases. The model can be utilized to guide the
laboratory towards the most informative experiments.

59

CHAPTER 4
BRIDGING THE MULTISCALE GAP: IDENTIFYING
CELLULAR PARAMETERS FROM MULTICELLULAR
DATA

4.1

Abstract
Multiscale models that link sub-cellular, cellular and multicellular components offer

powerful insights in disease development. Such models need a realistic set of parameters
to represent the physical and chemical mechanisms at the sub-cellular and cellular levels
to produce high fidelity multicellular outcomes. However, determining correct values for
some of the parameters is often difficult and expensive using high-throughput microfluidic
approaches. This work presents an alternative approach that estimates cellular parameters
from spatiotemporal data produced from bioengineered multicellular in vitro experiments.
Specifically, we apply a search technique to an integrated cellular and multicellular model
of retinal pigment epithelial (RPE) cells to estimate the binding rate and auto-regulation
rate of vascular endothelial growth factor (VEGF). Understanding VEGF regulation is
critical in treating age-related macular degeneration and many other diseases. The method
successfully identifies realistic values for autoregulatory cellular parameters that reproduce
the spatiotemporal in vitro experimental data.
0

The coauthors for this chapter are: Qanita Bani Baker, Gregory J. Podgorski, Christopher D. Johnson,
Elizabeth Vargis, and Nicholas S. Flann
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4.2

Introduction
An important aspect of computational systems biology is the investigation of dynamic

biological processes that operate across multiple temporal and spatial scales by constructing
and running multiscale models [2], [10], [15], [114], [115]. These models incorporate a set of
parameters that represent the physical and chemical properties of the biological system [116].
The parameters are used to define the components of the models that when simulated
reproduce the behavior of the biological system. Often the correct values of these parameters
are unknown or difficult to obtain [117], [118].
Recently, there has been an increase in the number of model-fitting methods proposed
to estimate model parameters’ values [119], [120], [121] from experimental data. Without
accurate estimations of parameters, predictions from simulation studies will most likely
be erroneous and provide little scientific insight and guidance in disease treatment [122].
This scenario can be ameliorated by fitting the model to experimental in vitro / in vivo
data [123] [124]. Finding the best-fit values for the unknown parameters enhances the
possibility of performing accurate quantitative predictions.
Vascular endothelial growth factor (VEGF) is a key promoter of angiogenesis and vascular development and is the target in numerous anti-angiogenic therapies [125]. Angiogenesis
is the growth of blood vessels from the preexisting vasculature, a process involved in the
physiological functions of several diseases, such as cancer and age-related macular degeneration (AMD). Moreover, in spite of substantial basic science and translational research to
develop anti-angiogenic therapies, many questions remain about the mechanisms of action
of angiogenic drugs, how and why several diseases such as AMD become resistant to the
treatment, or the patient conditions that can benefit most from these drugs [108]. For
these reasons, computational models of angiogenesis have been developed to simulate the
process and provide a framework for generating and testing hypotheses of VEGF-driven
processes [109, 126, 127]. Models have aided in the development of novel and effective antiangiogenic therapeutics that target VEGF regulation and receptors [116], [128, 129]. Advancing these computational approaches combined with progress in in vitro experimental
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studies will shed light on these issues by providing an effective framework for generating
and testing hypotheses related to VEGF regulation and transport in the tissue [109].
An essential mechanism for understanding VEGF’s role in disease development is its
auto-regulation. The rate of VEGF secretion is controlled through an auto-inhibitory regulatory mechanism where the VEGF concentration of a cell’s microenvironment downregulates the secretion of VEGF. This control loop enables a community of cells to maintain
a stable background concentration of VEGF [130]. Disruption of the loop is implicated in
multiple disease states.
This paper presents a method for accurately characterizing this auto-regulation, not
from microfluidic assays that interrogate individual or mixed cell populations but from
spatially organized multicellular experimental data sampled over time. As will be explained
later, spatiotemporal data provides unique insights because auto-regulation is inherently a
mechanism that is manifested over space and time. The rest of the paper is structured as
follows: First the experimental setup and computational model is described, along with the
specific autoregulatory parameters that are known and those to be estimated. Second, the
search method for finding the values for the parameters is described in detail. Next the
method is evaluated by validating the identified parameter values. Finally, a summary of
the method’s effectiveness and suggestions for future work are given.

4.3

Multicellular Experiment and Model
The experiment from which the unknown parameter values are derived employs bio-

engineered micropatterning techniques. The micropatterns form a regular arrangement of
circular 2D patches populated with cells surrounded by an exposed substrate. The exposed
regions emulate necrotic areas of the retinal tissue that result from repeated exposure to
reactive oxidative species, triggering neovascularization and exudative AMD [50]. Recreating these regular spatially organized cellular configurations is essential to understanding
the impact of local cell-cell and cell-environment interactions on VEGF autoregulation.
In the experimental study, described in [1], the bioengineered circular micro patterns
were employed to control the extent of cell-cell interactions, which occur within the patch,
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and cell-environment interactions, which occur at the perimeter. Several patch sizes were
used in this study (100 µm, 200 µm, 300 µm, and 400 µm) to sample the proportion of
cell-cell and cell-environment interactions in each experiment. Such sampling constrains the
possible parameter values. Each patch was seeded with retinal pigment epithelial (RPE)
cells and grown in a cellular culture. As the cells grew, the VEGF per cell was measured
at regular intervals: 4, 24, 30 48, 54, 72 h. To measure the VEGF per cell, enzyme-linked
immunosorbent assay (ELISA) was used to determine the total VEGF contained within the
cell culture, and the number of cells per patch was determined by image analysis proceeded
by staining. Figure 4.1(a) (taken from [1]) illustrates the stained patches at 72 hours.
Experiments were repeated ten times and averaged. The final spatiotemporal data produced
is illustrated in Figure 4.1(b) and forms the target prediction for the computational model
simulation.
The bioengineered experiments were simulated using a hybrid agent-based approach,
which is an extension of iDynoMiCs framework developed by the Kreft group at University
of Birmingham [55]. This model was selected because of its extensibility and easy of use. All
inputs to the model such as parameter values and initial condition are easily specified using
an XML document called the protocol file. Hybrid models integrate discrete components to
represent the cells and continuous equations to represent biochemical reactions and diffusion.
Each cell is a spherical particle that grows by consuming nutrient and accumulating biomass
volume; when the volume exceeds twice the initial volume, cell division is simulated by
splitting the particle into two. Particles can secrete and uptake soluble biochemicals (such
as VEGF) which diffuse through the domain; regulatory reactions that model interactions
among intracellular and inter-cellular proteins become PDEs. The simulation interlaces
cellular growth and movement (implemented by relaxing forces between particles) with
biochemical redistribution (implemented by solving the PDEs). Random noise disrupts
cellular movement and the division volume to represent the inherent stochasticity of the
biological processes.
The setup of the simulations replicate the experimental conditions and units of the
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in vitro experiments. The 2D domain size of each simulation is 2400µm by 2400 µm,
initial cell size is set to 80µm2 and the doubling time due to growth is set at 36 hours.
Each simulation begins with multiple RPE cells distributed randomly at the same density
and with the patch pattern. The simulation replicates the first 72 hours of the in vitro
experiments. Illustrations of the simulated experiments are shown in Figure 4.2.
This framework is inherently multiscale in that the parameters that control the low-level
mechanisms at the cellular level, e.g., growth, the VEGF secretion rate and autoregulation,
determine the cell population and VEGF concentration over the complete multicellular
domain. Figure 4.2 illustrate the VEGF distributions in the domain. To compute the
VEGF concentration per cell, the total VEGF is computed over the whole domain, while
the number of cells is directly determined by the simulator. This approach intrinsically
includes the quantitative spatiotemporal control effects as the cells grow, secret VEGF
which diffuses over the domain. Moreover, the simulations provide insight into the spatial
VEGF gradients within and between patches, unavailable in in vitro studies.
The autoregulation of VEGF secretion is described in Equation 4.1 as a function of
biomass M and local VEGF concentration V . The diffusion coefficient of VEGF, DV , is
set to 5.8 × 10−11 m2 s−1 given in microfluidic experiments from [112].
K
∂V
= DV 52 V + µV
M
∂t
βV + K

(4.1)

Over time, the RPE cells grow based on a doubling time of 36 hours [113], which determines the growth rate parameter µM . Since nutrient is unlimited and cell crowding is
not an issue within the 72 hour time line, we applied first order kinetics for cell growth as
shown in Equation 4.2.

∂M
= µM M
∂t

(4.2)

Table 4.1 summarizes the description of the parameters used in the equations above
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(a)

(b)
Figure 4.1. (a) Patches of stained RPE cells at 72 h for each patch size [1]. (b) Time course
of VEGF expression per cell measured at 4, 24, 30, 48, and 72 h (data for each time from
the in vitro [1]).

and identifies the known parameters and those that need to be determined by the method
introduced in this paper.
Table 4.1. Known and unknown parameter descriptions

4.4

Parameter

Value

Description

DV
µM

5.8 × 10−11 m2 s−1
1.0194 hour−1

Diffusion coefficient
Max. growth rate for RPE cells

K
µV
β

Unknown
Unknown
Unknown

Auto regulation rate
Secretion rate
Binding affinity

Method
In this work, we apply a parameter fitting technique to validate a hybrid agent-based

model with available in vitro experimental data in order to explore the best-fit values for
the unknown parameters given in Table 4.1. The three unknown parameters are termed
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(a)

(b)

(c)

(d)

Figure 4.2. (a) Closeup of initial condition of a 400 µm patch (b) Experiment with 400
µm, 3 patches in each side. (c) Closeup of the VEGF distribution after 72 h, (d) VEGF
distribution over whole domain after 72 h.
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Figure 4.3. An overview for the error-minimization multicellular search-based approach. In
(A), RPE cells are cultured using micropatterning techniques. In (B), the parameters are
initialized in the XML protocol file. In (C), a simulation is performed and the results are
calculated. In (D), the error is calculated based on the difference in VEGF concentration
per cell between the experimental results and simulation outputs as in Equation 4.3. Based
on the change in error, new parameter values are selected for another simulation run (E
and F). This process(B-F) will be repeated until an exit condition is met where the error
improvement is below a threshold value or the search time runs out.

the free parameters and together they define the vector P̄ =< K, µV , β >. We use an
error-minimization search approach that explores the space of free parameters and returns
the vector P̄ that yields the simulation results best fitting the experimental data [1]. The
fitting process is summarized as follows:
Given: Model free parameters, simulation outputs, and experimental in vitro data.
Find: Best-fit values for the free parameters (best P̄ )
Such: The error between the simulation and experimental in vitro data is minimized.
The search for the correct P̄ (described in Algorithm 1 and Figure 4.3) starts by
sweeping over an initial range of values for each free parameter being fitted. A single sweep
consists of running simulations for the space of P̄ (all combinations of free parameter values
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based on their ranges). The range is defined by a minimum value, a maximum value, and
a step value. In a sweep, each parameter starts from its minimum value and incrementally
increases to its maximum value by its step value. An error is calculated for each parameter
vector by comparing the time-series outputs of the simulation with experimental in vitro
data (see Figure 4.3D). The vector P̄ of parameter values with the minimum error is selected
and becomes the midpoint for the parameter ranges in the next sweep (see Figure 4.3E and
F). The process continues until an exit condition is met where the reduction in error is
below a threshold or the preset search time runs out. The parameter values (both free and
known parameters) for a simulation are specified via the protocol file. (see Figure 4.3B).
In this model, the error was calculated using Equation 4.3. Vs (i, t) and Ve (i, t) are the
VEGF concentrations per cell in the simulation and in vitro, respectively; i is the patch
size, i ∈ {100, 200, 300, 400µm} and t is the time in hours, t ∈ {4, 24, 30, 48, 54, 72 hours }.
The model error (εm) is the sum of the errors over the four patch sizes and six time points.
The error was calculated for each parameter vector P̄ . Additionally, since the simulation
process is stochastic, each simulation was repeated 10 times, starting from different random
seeds, and the results averaged for all presented data. Here it is important to note that this
approach could be used to fit other models using different parameters, experimental results,
and error functions.

εm =

XX
i

4.5

(Ve (i, t) − Vs (i, t))2

|P̄ =< K, µV , β >

(4.3)

t

Results
Initially the method was applied to a single parameter, K. Figure 4.4 shows the error

values for five sweep iterations over K. In each iteration, a parameter sweep for each patch
size was performed. In this run, the values of VEGF secretion rate µV and VEGF binding
rate β were set to 0.09 pg/ml and 1.0, respectively. In iteration 1 (It1) the parameters were
swept from 0.1 to 0.9, then the best value was chosen to determine the sweeping range for
iteration 2 (It2). Over repeated sweeps the range of possible valid values for K was greatly
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Algorithm 1 Algorithm for the Error-Minimization Search-Based approach using parameter sweeps which identifies a parameters vector P̄ that is locally optimal
1: Input: List of Free-Parameters P , XML Protocol Files Pf iles , and realistic parameter
ranges Rs.
2: For each parameter pk in P , initialize maxk , mink , stepk randomly within Rs.
3: while time-out is not reached and errorchange > errorthreshold do
4:
SW EEP (Pf iles , 1, max1 , min1 , step1 , {}, 10)
. Recursive parameter sweeping
algorithm. Started with the first parameter. See Algorithm 2
5:
For each simulation result from the space of P̄ s, calculate the VEGF concentration
per cell for each patch size i and time t
. There are 10 repeats for each simulation
using different random seeds
6:
Calculate the averageV EGF concentration
7:
Find the error based on equation 4.3
8:
errorchange = errorprevious - error
9:
if error < errorlowest then
10:
errorlowest = error
. Keep track of the lowest error found so far and the
change in error from the last sweep
11:
Change maxk , mink , stepk based on parameter values associated with error
12:
end if
13: end while
14: Return the parameters values P̄ associated with errorlowest . this will return the best
value(s) found

Figure 4.4. Error based on different K values with iteration number It

reduced. After five iterations of sweep processes, the best K value obtained was 0.13 and
the associated error was 1.01. This search considered many potential solutions and all but
one were rejected as sub-optimal.
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Algorithm 2 The parameter sweep algorithm that performs a simulation for all P̄ (a
combination of free parameters). Pf iles are the XML protocol files that define the model
input and initial condition, K is the parameter count, k is a counter that ranges from 1 to
K, maxk is the maximum value for parameter k, mink is the minimum value for the kth
parameter, and stepk is the value by which parameter k is incremented, P̄ holds a single
combination of parameter values for which a simulation will be performed, P is a matrix of
size Kxj where j is the number of values in the range of some parameter (which changes as
the algorithm progresses) and P[k][j] holds the jth value of the kth parameter, and RunN
is the number of repeated runs, each using different random seeds
2:

4:
6:
8:
10:
12:
14:
16:
18:

procedure Sweep(Pf iles , k, maxk , mink , stepk , P̄ , RunN )
if k = K then
Generate XML Protocol Files GP f iles with the same setup as in Pf iles with the
parameter values P̄
Run(GP f iles, PS et, RunN )
. random seeds runs
P̄ .Empty
else
j=1
P [k][j] = mink − stepk
while P [k][j] < maxk do
P [k][j] = P [k][j] + stepk
P̄ .Add(P [k][j])
j =j+1
k =k+1
SW EEP (GP f iles , k, maxk ,
mink , stepk , P̄ , 10)
end while
end if
end procedure

Figure 4.5 shows the error heat map of the first sweep iteration (It1) over two parameters (K and β). For this run, the VEGF secretion rate µV was set to 0.078 pg/ml/hour.
As shown, the error is lowest when the VEGF binding rate (β) is less than 0.3 and the K
value is greater than 0.03. Figure 4.6 shows the second sweep (It2), which has adjusted
sweeping ranges for K and β. Successive iterations refine the parameter values, as shown
through reduced error in Figure 4.7, which shows the third sweep (It3). The same sweeping
processes was also performed between (µV and K) and (µV and β) (data not shown).
To show how the concentration of VEGF changes over time in the simulation, VEGF
expression levels were calculated at various time intervals (4, 24, 30, 48, 54, 72 h). Figure

70

Figure 4.5. The heat map of error between K and VEGF binding coefficient/rate (β)
determined from the first round sweep.

Figure 4.6. The heat map of error between K and VEGF binding coefficient/rate (β)
determined from the second round sweep.

4.9(a) shows the data from in vitro and Figure 4.9(b) the in silico model, K, µV , and β
are set to 0.13, 0.09 and 0.85, respectively, which were determined from a near-optimal
solution discovered by the search method. The error associated with these results is 0.925.
As shown in figure 4.9(a) and 4.9(b), in both in silico and in vitro, RPE cells in the smaller
patches expressed higher levels of VEGF per cell. This indicates that these cells function to
maintain a consistent level of VEGF within their local microenvironment. Cells in smaller
patches respond by expressing higher amounts of VEGF because the VEGF expression
levels are dominated by cell-environment interactions. In contrast, larger patches maintain
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Figure 4.7. The heat map of error between K and VEGF binding coefficient/rate (β) from
the third round sweep.

lower basal levels of VEGF because cell-cell auto-inhibitory regulation dominates.
Now the parameters K, µV and β have been determined, we replace the variables with
their values in Equation 4.1 and set the mass M to that of a single cell (M = 25.95pg)
resulting in the VEGF autoregulatory function for RPE cells being:
dV
0.13
= 0.09 ×
× 25.95
dt
0.85V + 0.13

(4.4)

This function is plotted in Figure 4.8.

4.6

Conclusions
One of the main challenges in the computational modeling of biological systems is

the determination of the models’ parameters. This problem is particularly acute with
multiscale models that are gaining in popularity due to their realism. In this work, we
identified the parameter values of a cellular regulatory mechanism using spatiotemporal
multicellular data. While the problem of finding parameter values that describe the VEGF
autoregulatory mechanism of RPE cells is simple, this problem domain serves and a proofof-concept for the overall method. Most importantly, the method demonstrates that it is
possible to utilize data at one scale to determine parameter values at a different scale.
In the work presented here, thousands of simulations were performed as the search
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Figure 4.8. The VEGF autoregulatory function of RPE cells showing how the secretion rate
of VEGF is down regulated as a function of the VEGF in the microenvironment.

method explored the parameter space. For each potential solution, multiple simulations
were needed over each experimental case (different patch sizes) and because of the need for
repeats due to model stochasticity. For the simple 2D RPE model, each simulation took less
than a minute and so the process could be completed quickly. In general, the method can
rapidly become infeasible as the number of unknown parameters grows, domains become
larger and more complex, and the number of specific experimental cases grows.
A recently developed hybrid simulation system called Biocellion [114] could be used
instead of the iDynamics to speedup the rate of simulations. Biocellion can utilize thousands
of processing nodes and rapidly simulate complex models of billions of cells. The search
method utilized in this paper was chosen for its simplicity and insights on the local error
surfaces provided by the sweeping process. However, the fitting method is independent of
the method employed to search the parameter space. Alternative methods of combinatorial
optimization may improve performance.
One problem all fitting methods must deal with is under or over fitting the model.
There is a possibility that the fitting problem may be under-constrained for lack of data.
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(a)

(b)
Figure 4.9. (a) Time course of VEGF expression per cell measured at 4, 24, 30, 48, and 72
h (data from the in vitro work [1]. (b) Time course of VEGF expression per cell measured
at 4, 24, 30, 48, and 72 h (data from the in silico model after optimization).

This problem will be explored in the RPE domain by expanding the data set to include
additional studies with VEGF agonists and alternative pattern arrangements.
To extend the method to other domains, alternative error functions can be employed
that measure discrepancies over a diversity of spatiotemporal features which quantify both
the experimental observations and simulator outcomes. For instance, in [131] image processing is applied to bright field time-lapse images of growing yeast colonies to extract
trajectories of many visual features including volume, roughness, dominant frequency etc.
The same features could be extracted from the morphologies of simulated colonies and used
to fit parameters of the yeast model.
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CHAPTER 5
CONCLUSIONS
Computational biology is an integrative and holistic rather than reductionist approach
to understanding and controlling biological complexity [132]. It permits the development of
predictive and actionable models of multiscale biological systems that are vital to making
strides against the constellation of diseases that affect the world. These diseases are defined by their mechanistic complexity and nonlinearity, which spans several spatiotemporal
scales. The ability of agent-based modeling to encompass multiple spatiotemporal scales of
biological processes, suggests that this modeling framework is well suited for studying these
complex systems.
In this research, a multicellular hybrid agent-based modeling approach is utilized in
order to study disease development and progression, particularly in two applications: breast
cancer and bioengineered experiments. The models outlined were used to study in vitro
experimental work and in vivo development to gain new insights and integrate experimental
data to validate simulations.
In the first study, we developed a 2D agent-based model that attempted to emulate
the in vivo structure of breast cancer. The model was used to describe the transition from
DCIS into DCI. We concluded that the interaction between tumor cells and the surrounding
stroma in the duct plays a critical role in tumor growth and metastasis. This interaction
depends on many mechanical and chemical factors that work with each other to produce
tumor invasion of the surrounding tissue. In the second study, an in silico model was
proposed and applied to understanding the underlying mechanism of VEGF auto-regulation
in REP and emulate the in vitro experiments as part of bioengineering research. In the third
and final study, an innovative approach was presented that estimates cellular parameters
from spatiotemporal data produced from bioengineered multicellular in vitro experiments.
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We applied a search method to an integrated cellular and multicellular model of retinal
pigment epithelial cells to estimate the auto-regulation parameters of VEGF. This searching
method can be extended to other domains and alternative error functions, which can be
employed to measure discrepancies over a diversity of spatiotemporal features to quantify
both the experimental in vitro in vivo observations and simulator outcomes
From the studies performed in this research, we learned that models are more useful if
they can be predictive and the predictions are in a form that can be directly measured in
laboratory and clinical experiments. These predictive models can be utilized to guide the
laboratory towards the most informative experiments. To obtain such predictive models,
parameters estimation and models validation are essential. We have found that as granularity of model becomes more complex, the amount of data needed for validation becomes
greater than what can be generated by typical laboratory experiments, and so is often difficult to obtain. Finding the right model size is a challenge. The opportunities for the future
is to better understand how to take the large model, such as breast cancer it down to a level
where the parameters can be estimated robustly from experimental data, as illustrated in
the bioengineered application.
Future prospects for such modeling approaches include the development of patientcalibrated models by specialization of cell physiology obtained from clinical histopathology
data. These also include the creation of patient-specific digitized cell lines, which can then
be read by a collection of appropriate simulators to search, visualize, compare, predict, and
help guide the patient's treatment options. Attaining this future will require considerable
cooperation among in vitro research, clinical data, and computational biology work. Another developed hybrid simulation system called Biocellion [114] could be used instead of
the iDynamics to speed up the simulations. Biocellion has the ability to utilize thousands
of processing nodes and rapidly simulate complex models of billions of cells. Using the Biocellion framework, the models developed in this dissertation can be extends to large-scale
in order to support of high-throughput experiments and the discovery and evaluation of
therapies.
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Young, and A. G. Mikos, “Retinal pigment epithelial cell function on substrates with
chemically micropatterned surfaces.” Biomaterials, vol. 20, no. 23-24, pp. 2351–2361,
Dec. 1999. [Online]. Available: http://view.ncbi.nlm.nih.gov/pubmed/10614941
[102] L. Lu, K. Nyalakonda, L. Kam, R. Bizios, A. Göpferich, and A. G. Mikos, “Retinal
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